Document:

International Distribution Agreement

 EXHIBIT 10.36 
 INTERNATIONAL DISTRIBUTION AGREEMENT BETWEEN 
 CONOR MEDSYSTEMS IRELAND LTD. 
 AND

 INTERVENTIONAL TECHNOLOGIES LIMITED 
 THIS INTERNATIONAL DISTRIBUTION AGREEMENT (the “Agreement”) is made
and entered into as of April 1, 2006, by and between CONOR MEDSYSTEMS IRELAND LTD., an Irish corporation having its offices at IDA Business and Technology Park, Garrycastle,
Athlone, County Westmeath, Ireland (“Conor”), and INTERVENTIONAL TECHNOLOGIES LIMITED, an Indian corporation having its offices in Mumbai, India 201, Steel House, 2nd Floor 24,
Mahal Industrial Estate, Mahakali Caves Road, Andheri(E) Mumbai-400 093 (the “Distributor”). 
 WITNESSETH:

 WHEREAS, Conor owns certain proprietary drug-eluting stent products and related technology; 
 WHEREAS, Distributor desires an exclusive right to distribute a certain product in India, Pakistan, Bangladesh, Sri Lanka, Kenya,
and Tanzania; 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions herein
contained, and intending to be legally bound hereby, the parties mutually agree as follows: 
 1. PRODUCT AND
TERRITORY. 
 (a) Appointment. Subject to the terms and conditions of this Agreement, Conor hereby
appoints Distributor on an exclusive basis as its sole distributor in the Territory (as defined below) for the sale of the product listed in Exhibit A (the “Product”) during the term of this Agreement. 
 (b) Territory. Conor is appointing Distributor hereunder with respect to the resale of the Product to any purchasers whose
principal place of business is located in India, Pakistan, Bangladesh, Sri Lanka, Kenya, and Tanzania (the “Territory”). 
 (c) Activities outside the Territory. Distributor shall refrain from establishing or maintaining any branch, warehouse or distribution facility for the Product outside of the Territory. Distributor shall not
engage in any advertising or promotional activities relating to the Product directed primarily to customers outside the Territory. Distributor shall not solicit orders from any prospective purchaser with its principal place of business located
outside the Territory. Distributor shall not sell any Product to a purchaser if Distributor knows or has reason to believe that such purchaser intends to remove such Product from the Territory. 
 (d) Requests from outside the Territory. If Distributor receives any order from a prospective purchaser whose principal place of
business is located outside the Territory, Distributor shall immediately refer that order to Conor. Distributor shall not accept any such orders. Distributor may not deliver or tender (or cause to be delivered or tendered) any Product outside of the
Territory. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 1. 

 (e) Expansion of Products and Territory. Conor reserves the right, in its sole
discretion, at any time upon thirty (30) days’ prior written notice to Distributor, to expand or reduce in any manner the Product which is covered by this Agreement. Conor also reserves the right, in its sole discretion, at any time upon
thirty (30) days’ prior written notice to Distributor, to expand or reduce in any manner the Territory, as defined in this Agreement. 
 (f) Change of Control of Distributor. In the event of a Change of Control of Distributor, Conor shall have the right to appoint an additional distributor for the Territory, and the distributorship granted to
Distributor in Section 1(a) shall automatically convert from an exclusive appointment to a co-exclusive appointment. For the purpose of this Section 1(f), “Change of Control of Distributor” shall mean (i) any consolidation
or merger of Distributor with or into any other corporation or other entity or person, or any other corporate reorganization, in which the capital stock of Distributor immediately prior to such consolidation, merger or reorganization, represents
less than fifty percent (50%) of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (ii) any transaction or
series of related transactions to which Distributor is a party in which more than fifty percent (50%) of Distributor’s voting power is transferred to a third party; or (iii) the consummation of a sale of all or substantially all of
the assets of Distributor in any transaction or series of related transactions, other than a sale of all or substantially all of the assets of Distributor to an entity, more than fifty percent (50%) of the combined voting power of the voting
securities of which are owned by shareholders of Distributor in substantially the same proportions as their ownership of Distributor immediately prior to such sale. 
 2. PRICES AND PAYMENT. 
 (a) Ordering.
Distributor shall order the Product from Conor by submitting a written purchase order identifying the requested delivery date(s) and any export/import information required to enable Conor to fill the order. All orders for the Product are subject
to acceptance by Conor. Conor shall have no liability to Distributor with respect to purchase orders which are not accepted; provided, however, that Conor will not unreasonably reject any purchase order for the Product that meets the requirements of
this Section 2(a) and that does not request any modifications or additions to the Product. 
 (b) Pricing by
Conor. If a purchase order is accepted in accordance with Section 2(a) above, the price for the Product covered by such purchase order shall be in euros in accordance with the Product and Price List set forth in Exhibit A. Conor may from
time to time amend Exhibit A to change those prices, such change being effective immediately upon Distributor’s receipt of notice thereof; provided, however, that no price change shall affect purchase orders offered by Distributor and accepted
by Conor prior to the date such price change becomes effective. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 2.

 (c) Pricing by Distributor. Distributor shall be free to establish its own pricing
for the Product sold. Distributor shall notify Conor of its pricing, as in effect from time to time. 
 (d)
Limitations. The ultimate shipment of orders to Distributor shall be subject to the right and ability of Conor to make such sales and obtain required licenses and permits, under all decrees, statutes, rules and regulations of the government of
the United States and agencies thereof presently in effect or which may be in effect hereafter. 
 (e) Distributor
representations. Distributor hereby agrees: (i) to assist Conor in obtaining any required licenses, permits or approvals or complying with any other regulatory requirements in the Territory by providing all reasonably requested support,
including but not limited to supplying such documentation or information as may be requested by Conor; (ii) to comply with such decrees, statutes, rules and regulations of the government of the United States and agencies thereof; (iii) to
maintain the necessary records to comply with such decrees, statutes, rules and regulations; (iv) to not re-export any Product except in compliance with such decrees, statutes, rules and regulations; (v) to not sell, transfer, or otherwise
dispose of the Product in violation of the export laws of the United States; (vi) to translate to English and provide to Conor copies of any submissions made in accordance with this Section 2(e) or Section 30; and (vii) to
indemnify and hold harmless Conor from any and all fines, damages, losses, costs and expenses (including reasonable attorneys’ fees) incurred by Conor as a result of any breach of this subsection or subsection (f) below by Distributor or
any of Distributor’s customers. 
 (f) Export controls. Distributor hereby expressly acknowledges that the
technical data and the direct product thereof are subject to export controls of the United States and agrees that neither the technical data nor the direct product thereof will be transferred, directly or indirectly, to any destination contrary to
the requirements of the law of the United States, including but not limited to the terms of any export license and the terms of Part 774 (re-exports) of the U.S. Export Administration Regulations. Further, Distributor hereby provides its assurance
that it will not participate in any transaction which may involve any commodity or technical data, or the direct product thereof, exported or to be exported from the United States, or in any re-export thereof, or in any other transaction that is
subject to export controls of the United States, if a person denied export privileges from the United States may obtain any benefit from or have any interest in, directly or indirectly, these transactions. 
 (g) Packing and shipment. Unless Distributor requests otherwise, all Product ordered by Distributor shall be packed for shipment
and storage in accordance with Conor’s standard commercial practices. It is Distributor’s obligation to notify Conor of any special packaging requirements (which shall be at Distributor’s expense). Risk of loss and damage to a Product
shall pass to Distributor upon the delivery of such Product to the common carrier designated by Distributor FCA (Incoterms 2000). All claims for non-conforming shipments must be made in writing to Conor within ten (10) days of the passing of
risk of loss and damage, as described above. Any claims not made within such period shall be deemed waived and released. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 3.

 (h) Payments. All amounts due and payable with respect to a Product delivered by
Conor in accordance with the preceding subsection shall be paid in full within thirty (30) days after date of invoice covering such Product. All such amounts shall be paid in euros by wire transfer, to such bank or account as Conor may from
time to time designate in writing. Whenever any amount hereunder is due on a Business Day, such amount shall be paid on the next such Business Day. For the purpose of this Agreement, a “Business Day” shall mean a day on which banks in
Dublin, Ireland are open for business. Amounts hereunder shall be considered to be paid as of the day on which funds are received by Conor or into Conor’s account. No part of any amount payable to Conor hereunder may be reduced due to any
counterclaim, set-off, adjustment or other right which Distributor might have against Conor, any other party or otherwise. 
 (i) Letter of Credit. For each and every Distributor purchase order submitted according to Section 2 (a), Distributor shall deliver to Conor, as collateral for the full and faithful performance by Distributor of all of its
obligations under this Agreement, an irrevocable and unconditional negotiable letter of credit (the “Letter of Credit”) in the amount of the purchase order (the “LC Amount”), payable at sight. Such Letter of Credit shall
be issued by a solvent nationally recognized United States or European bank or financial institution with a long term debt rating of BBB or higher, (as rated by Standard & Poor’s) or Baa or higher (as rated by Moody’s Investors
Service) that has a branch office in Dublin, Ireland, from which Conor may draw on such Letter of Credit. The Letter of Credit shall (i) remain valid and subject to the terms of this Section 2(i) for the term of the Agreement, and if the
Letter of Credit is replaced, renewed, or extended during the term of this Agreement, Distributor shall deliver a new Letter of Credit or certificate of renewal or extension to Conor at least thirty (30) days prior to the expiration of the
expiring Letter of Credit, without any action whatsoever on the part of Conor; (ii) be subject to the Uniform Customs and Practices for Documentary Credits, ICC Publication No. 500, (iii) be fully assignable by Conor; and
(iv) permit partial draws. In addition to the foregoing, the form and terms of the Letter of Credit (and the bank issuing the same) shall be acceptable to Conor, in Conor’s sole discretion, and shall provide, among other things, that:
(A) such Letter of Credit shall be irrevocable, unconditional, and payable at sight; (B) Conor, or its then managing agent, shall have the right to draw down an amount up to the face amount of the Letter of Credit upon the presentation to
the issuing bank of Conor’s statement that such amount is due to Conor under the terms and conditions of this Agreement, it being understood that such statement shall be signed by any member of the senior management of Conor and; (C) the
Letter of Credit will be honored by the issuing bank without inquiry as to the accuracy thereof and regardless of whether the Distributor disputes the content of such statement. 
 (j) Interest. All amounts due and owing to Conor hereunder but not paid by Distributor on the due date thereof shall bear interest
(in euros) at the rate of the lesser of: (i) [ * ] per annum above the then-current EURIBOR (European Interbank Offering Rate); and (ii) the maximum lawful interest rate permitted under applicable law. Such interest shall accrue on
the balance of unpaid amounts from time to time outstanding from the date on which portions of such amounts become due and owing until payment thereof in full. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 4.

 (k) Purchase order discrepancy. In the event of any discrepancy between any
purchase order accepted by Conor and this Agreement, the terms of this Agreement shall govern. 
 (l) Principle ordering
terms. The Product shall be purchased and sold hereunder on the terms and conditions specified in Conor’s principle ordering terms, as set forth in Exhibit B. Conor shall have the right to modify such terms and conditions, on at least
thirty (30) days’ prior written notice to Distributor. In the event of any discrepancy between such terms and conditions and this Agreement, the terms of this Agreement shall govern. 
 (m) Fees. Distributor shall pay any and all fees, costs and expenses related to obtaining any required licenses, permits or
approvals in the countries of the Territory, including any fees, costs and expenses related to or derived from conducting clinical trials, studies or registries, provided, however, Conor agrees to pay up to a total of [ * ] euros for fees,
costs and expenses related to or derived from conducting clinical trials, studies or registries. 
 (n) Sale or import
without regulatory approval. Conor shall not be responsible for any sale or import of the Product into any countries or regions in which the Product has not received relevant national or supranational regulatory approvals that are legally
required by applicable laws of such country or region. Distributor hereby agrees to indemnify and hold Conor harmless from any damage, costs or liabilities (including reasonable attorneys’ fees) arising out of any claims, demands, suits, or
actions, to the extent arising or resulting from any sale or import into a certain country or region by Distributor without the necessary regulatory approval. 
 3. OTHER OBLIGATIONS OF DISTRIBUTOR. 
 (a) Facilities and resources. Distributor shall employ competent and experienced service personnel, provide appropriate facilities and resources so as to render prompt and adequate service to the users of the
Product in the Territory, and so as to comply with all of Distributor’s obligations under this Agreement. Distributor shall provide adequate and appropriate training to its staff concerning the Product. 
 (b) Promotional Materials. Distributor shall use sales and technical literature as well as promotional artwork and training
materials provided by Conor. Distributor may alter such materials or develop any other materials in connection with the marketing and distribution of the Product (including but not limited to product brochures and sales aids), subject to
Conor’s review and written approval prior to any use of such materials. Conor shall retain all right, title and interest in and to such materials. 
 (c) Customer Service. Distributor shall provide customer service (including, but not limited to, taking orders, responding to customer inquiries, fulfilling requests for quotes on Product pricing, and
forwarding Product complaints to Conor as legally required) on a timely basis and shall provide such assistance and information to customers as is reasonably requested by Conor. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 5.

 (d) No debarred or disqualified persons. Distributor warrants that it shall not
employ, contract with, or retain any person directly or indirectly to perform services under this Agreement if such person is (i) debarred by either the U.S. Food and Drug Administration under 21 U.S.C. § 335(a) or any equivalent law or
regulation in the Territory, or (ii) disqualified as described in 21 C.F.R. § 812.119, or any equivalent law or regulation in the Territory. In the event that Distributor becomes aware of the debarment or disqualification of any person
providing services to Distributor which relate to services being provided under this Agreement, Distributor agrees to notify Conor immediately. 
 (e) Translations. Distributor shall translate, at its own expense, all user and technical manuals, and advertising and marketing information into the languages of its customers and provide Conor with advance
copies of all such materials for approval by Conor. Conor shall own such translations and related intellectual property rights, but Distributor has a non-exclusive right to use such translations during the term of this Agreement in connection with
its activities pursuant to this Agreement. 
 4. CONOR’S OBLIGATIONS. 
 (a) Assistance. Conor shall provide Distributor with such marketing and technical assistance and free Product samples as Conor may
in its discretion consider necessary to assist with the promotion of the Product. 
 (b) Training. Conor shall provide
product launch training to Distributor’s personnel in connection with the marketing, sale, maintenance and support of the Product. 
 (c) Maintenance. Conor shall designate maintenance and support personnel to assist Distributor’s support personnel in providing maintenance and support services. 
 5. RELATIONSHIP OF THE PARTIES. 
 (a) Independent contractor. Distributor shall be considered to be an independent contractor. The relationship shall not be
construed to be that of employer and employee, nor to constitute a partnership, joint venture or agency of any kind. 
 (b)
Expenses. Distributor agrees to pay, and shall solely bear, all of its incurred expenses in connection with this Agreement, including without limitation all travel, lodging and entertainment expenses. 
 (c) Distributor not to enter contracts that bind Conor. Distributor shall have no right to enter into any contracts or commitments
in the name of, or on behalf of, Conor, or to bind Conor in any respect -whatsoever. 
 (d) No obligations to third
parties. In addition, Distributor shall not obligate or purport to obligate Conor by issuing or making any affirmations, representations, warranties or guaranties with respect to the Product to any third party. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 6.

 6. BEST EFFORTS. 
 (a) Distributor to use best efforts. Distributor agrees, for the term of and subject to the provisions of the term of this
Agreement, to use its best efforts to promote and market the Product to the maximum number of customers in the Territory. Distributor and Conor shall mutually agree in writing on the sales promotion activities and performance objectives to be met by
Distributor for Conor’s fiscal year. Distributor shall provide Conor with an annual analysis of the market, including market size, market share data, and competitive activities. Such information shall be provided to enable Conor in developing
the global marketing and business plans for the mutual advantage of Distributor and Conor. Upon signing this Agreement, Distributor and Conor will jointly establish Distributor’s performance objectives for Conor’s fiscal year. The
establishment of performance objectives will be repeated annually. The established performance objectives will become a part of this Agreement, and will be attached hereto as Exhibit C. 
 (b) Failure to use best efforts. Failure to meet any minimum established performance objectives shall constitute a material breach
of this Agreement for the purposes of Article 14. 
 7. REPORTING. 
 (a) Customer reports. Distributor shall provide Conor with written quarterly reports, which shall include customer call reports,
business trends, sales forecasts for the significant customers in the Territory, market forecasts and other reports requested by Conor. 
 (b) Adverse Event Reporting. Distributor shall notify Conor immediately of (i) all adverse comments or complaints by Distributor’s customers regarding the Product, including comments regarding the
Product’s quality, stability, contamination, potency, condition, packaging, or any other attributes or defects, and (ii) all adverse events and adverse reactions that may be attributable to a customer’s use of the Product, whether or
not Distributor can confirm that the event is actually associated with the Product, and whether or not Distributor can confirm that the event was due to improper dosing or other negligence on the part of the physician or patient. Distributor shall
provide Conor with information regarding the reporting requirements in the Territory. 
 (c) Alleged Defects. In the
event of an actual or alleged malfunction or defect of a Product, Distributor or its representatives or agents shall not make any statement as to the cause, prior to receiving Conor’s written analysis of such malfunction or defect, and shall
thereafter make no statements contrary to or inconsistent with the results of such analysis. 
 (d) Product Recall. If
either Party believes that a recall of any Product in the Territory is desirable or required by law in the Territory or elsewhere, it shall immediately notify the other Party. The Parties shall then discuss reasonably and in good faith whether such
recall is appropriate or required and the manner in which such recall should be handled. 
 (e) Remedial Actions. It is
Conor’s exclusive right to issue recalls, safety alerts, advisory notices or similar remedial actions with respect to the Product. In the event of such remedial action, Distributor will support and fully cooperate with Conor to comply with
applicable laws and regulations, and Distributor will notify its customers and, upon Conor’s request, retrieve the identified Product. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 7.

 8. FIELD ASSISTANCE. Conor shall provide, in its discretion,
appropriate field technical assistance to Distributor and Distributor’s customers. 
 9. TRADEMARKS,
SERVICE MARKS AND OTHER INTELLECTUAL PROPERTY. 
 (a) Intellectual Property. Distributor may use Conor’s trade names, trademarks and service marks that are designated by Conor for each Product (the “Conor Intellectual Property”) on a
non-exclusive basis in the Territory, only for the duration of this Agreement and solely in connection with selling, marketing and distributing the Product in accordance with this Agreement. Distributor shall, upon Conor’s request, cooperate
with Conor in any action necessary or desirable to register with the appropriate governmental agencies any Conor trademark used or proposed to be used hereunder, and to protect any Conor trademark proposed to be used. Distributor shall not at any
time do or permit any act to be done which may in any way impair the rights of Conor in the Conor Intellectual Property or the value of the Conor Intellectual Property. 
 (b) Quality Control. In order to comply with Conor’s quality control standards, Distributor shall: (i) use the Conor
Intellectual Property in compliance with all relevant laws and regulations; (ii) accord Conor the right to inspect during normal business hours, without prior advance notice, Distributor’s facilities used in connection with efforts to
store or sell the Product in order to confirm that Distributor’s use of such Conor Intellectual Property is in compliance with this provision; and (iii) not modify any of the Conor Intellectual Property in any way and not use any of the
Conor Intellectual Property on or in connection with any goods or services other than the Product. 
 (c) Inventions.
Any inventions made, developed, conceived, or reduced to practice by Distributor that relate to the Product (including any associated delivery systems), and any intellectual property relating thereto, shall be owned solely by Conor. Distributor
hereby assigns and transfers to Conor all right, title, and interest in and to such inventions and related intellectual property and agrees to take all further acts reasonably required to evidence such assignment and transfer to Conor, all at
Conor’s expense. Conor hereby grants to Distributor a nonexclusive, royalty-free, nontransferable, nonsublicenseable license to such inventions made by Distributor for uses other than in the Product and associated delivery systems. 

(d) Notice of Intellectual Property Infringement. Distributor shall promptly notify Conor in writing of any patent or copyright
infringement or unauthorized use of Conor trade secrets or trademarks in the Territory of which Distributor becomes aware. Conor shall have the exclusive right in its sole discretion to institute any proceedings against such third party in its name
and on its behalf. Distributor shall cooperate fully with Conor in any legal action taken by Conor against such third parties, provided that Conor shall pay all expenses of such action and all damages relating to damage suffered personally by Conor
which may be awarded or agreed upon in settlement of such action shall accrue to Conor. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 8.

 10. COVENANT NOT TO COMPETE. During
the term of this Agreement, Distributor shall not market directly or indirectly in the Territory any drug-eluting stent products. In the event the Distributor breaches the terms of this Section 10, Distributor’s appointment as exclusive
distributor of the Product under Section 1(a) will convert to an appointment as a non-exclusive distributor of the Product, which remedy shall not be exclusive of, and shall be in addition to, any other remedies available to Conor at law or in
equity with respect to such breach. 
 11. LIMITED WARRANTY. 
 (a) Representations by Conor. As to all components of the Product manufactured by Conor, Conor warrants that, at the time of
shipment, the Product supplied by Conor hereunder (i) shall meet the Product specifications agreed to in writing by the parties, (ii) shall not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act (the
“Act”) or other applicable laws that are equivalent thereto in the Territory, and in which the definitions of adulteration and misbranding are substantially the same as those contained in the Act, (iii) shall be manufactured in
accordance with Good Manufacturing Practices as defined in the Act and the World Health Organization Guidelines; provided, however, that Conor shall not be liable for any of the foregoing with respect to any product labeling or package inserts to be
provided or used by Distributor, or any translation thereof, or for any noncompliance with the foregoing due to the handling or packaging of the Product by Distributor. 
 (b) Limitations. Under no circumstances shall the warranties set forth in Section 11(a) apply to any Product which has been
used with unapproved components or to any Product which has been customized or modified, damaged, reused, or misused. In the event that the warranties set forth in Section 11(a) are breached and Conor is responsible for such breach, Conor will
replace the defective product at no cost to Distributor. THE PROVISIONS OF THE FOREGOING WARRANTIES ARE IN LIEU OF ANY OTHER WARRANTY, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE). CONOR’S LIABILITY ARISING OUT OF THE MANUFACTURE, SALE OR SUPPLY OF THE PRODUCT UNDER THIS AGREEMENT OR THE USE OR DISPOSITION OF THE PRODUCT BY DISTRIBUTOR OR ITS CUSTOMER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT OR OTHERWISE,
SHALL NOT EXCEED THE ACTUAL PURCHASE PRICE PAID BY DISTRIBUTOR FOR THE PRODUCT. IN NO EVENT SHALL CONOR BE LIABLE TO DISTRIBUTOR OR ANY OTHER PERSON OR ENTITY FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF
PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES) ARISING OUT OF THE MANUFACTURE, SALE OR SUPPLY OF THE PRODUCT EVEN IF CONOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 9.

 12. REPRESENTATIONS BY DISTRIBUTOR;
DISTRIBUTOR COVENANTS. 
 (a) Distributor hereby represents and warrants to Conor
that, as of the Effective Date: 
 (i) it is qualified and permitted to enter into this Agreement and that the terms of
this Agreement do not conflict with and are not inconsistent with any other of its contractual obligations; 
 (ii) it
is validly existing and in good standing as a corporation under the laws of India, and has all necessary corporate power to perform its obligations under this Agreement and its financial resources are sufficient to enable it to perform all of its
obligations under this Agreement; 
 (iii) it has not at any time in the past three (3) years been involved, and
is not currently involved, in any litigation or disciplinary action relating to the sale of medical devices before a regulatory authority or under the laws of any country, and to its knowledge no such proceedings are anticipated to commence during
the term of this Agreement; 
 (iv) it has sufficient personnel and capacity to perform its obligations under this
Agreement; and 
 (v) it owns or controls sufficient rights for it to perform its obligations under this Agreement.

 (b) Distributor hereby covenants that Distributor (a) shall store the Product in accordance with the storage
specifications that Conor will provide in writing, and in accordance with all applicable laws, rules and regulations in the Territory, (b) shall distribute and ship the Product within the Territory in accordance with Conor’s packaging,
shipping and distribution specifications for the Product that Conor will provide in writing, and in accordance with all laws, rules and regulations in the Territory, (c) shall not sell any Product with an expired shelf life, and shall dispose
of any such expired Product in the manner required by Conor, and in accordance with all laws, rules and regulations in the Territory, (d) shall not adulterate or misbrand the Product, or engage in any activity that could or does render the
Product adulterated or misbranded, and (e) shall maintain all necessary records for compliance with all laws, rules and regulations in the Territory. 
 13. INDEMNIFICATION IN FAVOR OF CONOR. 
 (a) Indemnification. Distributor shall indemnify, protect and save Conor, its Affiliates (as defined below) and all officers, directors, employees and agents thereof (hereinafter referred to as
“Indemnitees”) harmless from all claims, demands, suits or actions (including attorneys’ fees incurred in connection therewith) which may be asserted against Conor for any kind of damages, including without limitation damage or
injury to property or persons and incidental and consequential damages, which may be sustained by any third party or any of the Indemnitees arising out of or incident to the conduct of Distributor’s operations under this Agreement. For the
purpose of this Agreement, “Affiliate” shall mean, with respect to a party, any company, natural person, partnership or 

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 10.

 
other business entity that controls, is controlled by, or is under common control with such party, where the term “controls” denotes the ownership,
directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether
through the ownership of voting securities, by contract, or otherwise (with correlative definitions for the terms “controlled by” and “common control”). 
 (b) Insurance. During the term of this Agreement and for four (4) years thereafter, Distributor shall maintain an insurance
policy issued by a reputable insurance company, naming Conor as an additional insured, which policy shall insure against any and all claims, liabilities, costs or expenses resulting from or caused by (or claimed to be resulting from or caused by)
any use or operation of any products sold by Distributor in the amount of at least [ * ] euros per claim, and [ * ] euros for claims in the aggregate. 
 14. TERMINATION. 
 (a) Term. The term of this Agreement shall
begin on April 1, 2006 (the “Effective Date”) and shall terminate, unless terminated earlier pursuant to the terms of this Section, on December 31, 2008 (the “Term”). The Term shall be renewable for
additional one (1) year terms on the mutual written agreement of the Parties. Approximately three (3) months prior to the end of the Term, the parties will discuss the possible extension or renewal of this Agreement, which will be based on
a mutually acceptable performance objective. 
 (b) Termination. Conor may terminate this Agreement at any time upon
ninety (90) days written notice to Distributor. 
 (c) Termination for material breach. Upon the occurrence of a
material breach or default as to any obligation hereunder by either party and the failure of the breaching party to cure such material breach or default within thirty (30) days after receiving written notice thereof from the non-breaching
party, this Agreement may be terminated by the non-breaching party by giving written notice of termination to the breaching party, such termination being immediately effective upon the giving of such notice of termination. Material breach includes,
but is not limited to the following: (i) breach by Distributor of the provisions set forth in Article 1 above; (ii) impairment by Distributor of Conor’s rights in the Conor Intellectual Property, in violation of Article 9 above;
(iii) breach by Distributor of the Foreign Corrupt Practices Act; (iv) failure of Distributor to make any payments timely and in accordance with this Agreement; (v) failure to establish and maintain clinical specialists and a sales
organization to adequately and effectively sell the Product within the Territory; (vi) failure to use best efforts or order minimum quantities in accordance with Section 6(a) and Exhibit C; (vii) engaging in any act that is
detrimental to Conor, the Product, or Conor’s reputation; or (viii) any breach of any covenant, representation or warranty in this Agreement, including but not limited to Sections 2(e), 3(a), 5(b), 5(d) and Article 12. 
 (d) Change of Control of Distributor. In the event of a Change of Control of the Distributor, Conor may terminate this Agreement by
giving written notice of termination to Distributor, such termination being immediately effective upon the giving of such notice of termination. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 11.

 (e) Bankruptcy. Upon the filing of a petition in bankruptcy, insolvency or
reorganization against or by either party, or either party becoming subject to a composition for creditors, whether by law or agreement, or either party going into receivership or otherwise becoming insolvent (the “Insolvent
Party”), this Agreement may be terminated by the other party by giving written notice of termination to the Insolvent Party, such termination immediately effective upon the giving of such notice of termination. 
 (f) No compensation. In the event of a termination pursuant to any of subsections (b), (c), (d), or (e) above or upon
expiration of this Agreement pursuant to subsection (a) above, Conor shall not have any obligation to Distributor, or to any employee of Distributor, for compensation or for damages of any kind, whether on account of the loss by Distributor or
such employee of present or prospective sales, investments, compensation or goodwill. Distributor, for itself and on behalf of each of its employees, hereby waives any rights which may be granted to it or them under the laws and regulations of the
Territory or otherwise which are not granted to it or them by this Agreement. Distributor hereby indemnifies and holds Conor harmless from and against any and all claims, costs, damages and liabilities whatsoever asserted by any employee, agent or
representative of Distributor under any applicable termination, labor, social security or other similar laws or regulations. 
 (g) Payments owed on termination. Termination of this Agreement shall not affect the obligation of Distributor to pay Conor all amounts owing or to become owing as a result of the Product tendered or delivered to Distributor on or
before the date of such termination, as well as interest thereon to the extent any such amounts are paid after the date they became or will become due pursuant to this Agreement. 
 (h) Transfer of Licenses, Permits and Approvals. Upon termination of this Agreement, Distributor shall transfer, if legally able to
do so, to Conor any and all licenses, permits and approvals that Distributor obtained in accordance with Section 30. 
 (i) Surviving provisions. Notwithstanding anything else in this Agreement to the contrary, the parties agree that Sections 2(e), 2(f), 3(b) and Articles 7 (as to the Product sold during the term), 9, 11(b), 13, 14, 15, 19, 20, 22,
24, 26, 27, 30, and 31 shall survive the termination or expiration of this Agreement, as the case may be, to the extent required thereby for the full observation and performance by any or all of the parties hereto. 
 15. SELL-OFF PERIOD; REPURCHASE OF INVENTORY.

 (a) Sell-Off Period. Upon termination or expiration of this Agreement other than by Conor pursuant to
Section 14(c) or Section 14(d), Distributor shall have the right to sell off its remaining inventory of the Product on a non-exclusive basis for four (4) months after such termination or expiration or for so long as such inventory
exists, whichever is shorter; provided, however, that Distributor shall comply with all terms and conditions of this Agreement, including those that restrict reselling activities, in effect immediately prior to termination or expiration.
Distributor’s rights under this Section 15(a) are expressly subject to Conor’s option to repurchase Distributor’s inventory of the Product, as set forth in Section 15(b). 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 12.

 (b) Option to repurchase. Upon either termination or expiration of this Agreement,
as the case may be, Conor shall have the option to repurchase Distributor’s inventory of the Product, which option must be exercised in writing within thirty (30) days after such termination or expiration. If Conor so exercises such
option, Conor shall repurchase Distributor’s inventory of Products that are saleable and in the original packages and unaltered from their original form and design, subject to Conor’s inspection, test, and acceptance. 
 (c) Repurchase price. Any such repurchase of Distributor’s inventory of Products shall be at [ * ]. Repurchased
inventory shall be shipped by Distributor freight prepaid, according to Conor’s instructions. Conor shall pay Distributor for such repurchased Products within thirty (30) days after Conor receives those Products in one of its facilities.

 16. PUBLICITY. Distributor agrees that any publicity or advertising which shall be released by it in which Conor is
identified in connection with the Products shall be in accordance with the terms of this Agreement and with any information or data which Conor has furnished in connection with this Agreement. Copies of all such publicity and advertising shall be
forwarded promptly to Conor. 
 17. MODIFICATION. No modification or change may be made in this Agreement except by
written instrument duly signed by Distributor and by a duly authorized representative of Conor. 
 18. ASSIGNMENT.
Distributor may not assign all or any part of its rights and obligations under this Agreement to anyone without the prior written consent of the Conor. Conor may assign its rights and obligations under this Agreement to (a) any of its
Affiliates, (b) any person or entity to whom Conor licenses or otherwise transfers the right to manufacture Product (subject to appropriate written notice to Distributor to facilitate any necessary change in Government Approvals), or
(c) any person or entity with which Conor is merged or by which it is acquired or which purchases all or substantially all of its assets; provided that any such assignee agrees to abide and perform all Conor’s obligations and duties under
this Agreement. Conor shall notify Distributor of any such assignment. Any prohibited assignment shall be null and void. 
 19.
NOTICE. All notices given under this Agreement shall be in writing and shall be addressed to the parties at their respective addresses set forth below: 
 IF TO DISTRIBUTOR: 
 INTERVENTIONAL TECHNOLOGIES LIMITED 
 Mumbai, India 201, Steel House, 2nd Floor 24, 
 Mahal Industrial Estate, Mahakali Caves Road, 
 Andheri(E) Mumbai-400 093 India 
 Fax: 001-91-22-26873706 
 Attention: Vali Kasim 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 13.

 IF TO CONOR: 
 CONOR MEDSYSTEMS IRELAND LIMITED 
 IDA Business and Technology Park, Garrycastle 
 Athlone, County Westmeath, Ireland 
 Fax: +353 (0) 9064 71100 
 Attention: James Hallums 
 Either party may change its address or its telecopy or fax number for purposes of this Agreement by giving the other party written notice of its new address or telecopy
number. Any such notice if given or made by registered or recorded delivery international air mail letter shall be deemed to have been received on the earlier of the date actually received and the date fifteen (15) calendar days after the same
was posted (and in providing such it shall be sufficient to prove that the envelope containing the same was properly addressed and posted as aforesaid) and if given or made by telecopy transmission shall be deemed to have been received at the time
of dispatch, unless such date of deemed receipt is not a Business Day, in which case the date of deemed receipt shall be the next such succeeding Business Day. 
 20. WAIVER. None of the conditions or provisions of this Agreement shall be held to have been waived by any act or knowledge on the part of either party, except by an instrument in writing signed
by a duly authorized officer or representative of the parties. Further, the waiver by either party of any right hereunder or the failure to enforce at any time any of the provisions of this Agreement, or any rights with respect thereto, shall not be
deemed to be a waiver of any other rights hereunder or any breach or failure of performance of the other party. 
 21.
VALIDITY. Distributor warrants that this Agreement is lawful and may be performed in accordance with its terms under all laws in force in India and all of the countries comprising the Territory at the time of execution of this
Agreement. Conor and Distributor covenant and warrant that they will each advise the other of any changes in the respective laws of which they become aware which might or will impair the validity of all or any part of this Agreement. 
 22. CONSTRUCTION OF AGREEMENT AND RESOLUTION OF
DISPUTES. This Agreement shall be interpreted in accordance with the commonly understood meaning of the English words and phrases hereof in United Kingdom, and it and performance of the parties hereto shall be construed and
governed according to the laws of the United Kingdom, without regard to conflicts of law principles that would provide for application of the law of a jurisdiction outside of the United Kingdom. The Parties agree that the United Nations Convention
on Contracts for the International Sale of Goods (CISG) does not apply to this Agreement. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 14.

 (a) Right to judicial proceedings. Each party shall have the right to institute
judicial proceedings against the other party or anyone acting by, through or under such other party, in order to enforce the instituting party’s rights hereunder through reformation of contract, specific performance, injunction or similar
equitable relief. 
 (b) Jurisdiction. The parties irrevocably submit to the jurisdiction of the state and federal
courts of the United Kingdom; provided, however, that nothing herein shall preclude either party from instituting proceedings against the other party or anyone acting by, through or under the other party in any place which may have jurisdiction for
the purpose of protecting and enforcing such party’s rights either hereunder or pursuant to any other agreements, documents, instruments or otherwise. 
 (c) Service by mail. In the alternative, service of process may be made by postage prepaid registered or recorded delivery air-mail letter transmitted by either party to the other party at the address for
notices set forth above for such other party with a duplicate copy sent by postage prepaid registered or recorded delivery air mail letter to the agent appointed by such other party hereunder. 
 (d) Waiver of objection. Each party hereby irrevocably waives any objection which it may now or hereafter have to the laying of
venue of any suit, action or proceeding relating to this Agreement in United Kingdom and further irrevocably waives any claim that the United Kingdom is not a convenient forum for any such suit, action or proceeding. 
 23. CONOR OFFICE IN THE TERRITORY. Conor may from time to time maintain
an office at one or more locations in or near the Territory. Personnel associated with such office or offices shall be authorized to and may, from time to time, act on behalf of Conor and shall be entitled to exercise all of the rights of Conor
under this Agreement. Such personnel shall be entitled to all information with respect to all matters relevant to Distributor’s performance under the Agreement, and Distributor shall at all times cooperate with such personnel with respect to
all such matters. 
 24. CONFIDENTIALITY MAINTAINED. 
 (a) Proprietary Information. Distributor agrees that Conor has a proprietary interest in any information provided to Distributor by
Conor, whether in connection with this Agreement or otherwise, whether in written or oral form, which is (i) a trade secret, confidential or proprietary information, and (ii) not publicly known (the “Proprietary
Information”). Distributor shall disclose the Proprietary Information only to those of its agents and employees to whom it is necessary in order to carry out their duties properly as limited by the terms and conditions hereof. Both during
and after the term of this Agreement, all disclosures by Distributor to its agents and employees shall be held in strict confidence by such agents and employees. During and after the term of this Agreement, Distributor, its agents and employees
shall not use the Proprietary Information for any purpose other than in connection with Distributor’s sale and distribution of the Products in the Territory pursuant to this Agreement. Distributor shall, at its expense, return to Conor the
Proprietary Information as soon as practicable after the termination or expiration of this 

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 15.

 
Agreement. All such Proprietary Information shall remain the exclusive property of Conor during the term of this Agreement and thereafter. This
Section 24(a) shall also apply to any consultants or subcontractors that Distributor may engage in connection with its obligations under this Agreement. 
 (b) Permitted disclosure. Notwithstanding anything contained in this Agreement to the contrary, Distributor shall not be liable for
a disclosure of the Proprietary Information of Conor, solely to the extent that the information so disclosed: (i) was in the public domain at the time of disclosure without breach of this Agreement; or (ii) was known to or contained in the
records of Distributor from a source other than Conor at the time of disclosure by Conor to Distributor and can be so demonstrated by competent written records; or (iii) was independently developed and is so demonstrated promptly upon receipt
of the documentation and technology by Distributor; or (iv) becomes known to Distributor, without any restrictions on further disclosure, from a source other than Conor without breach of this Agreement by Distributor and can be so demonstrated
by competent written records. 
 25. ENTIRE AGREEMENT. This Agreement, including all Exhibits and
appendices hereto, supersedes, terminates and cancels any previous agreements or understandings, including the International Distribution Agreement between Conor and Distributor, dated July 1, 2004 (except for the surviving provisions of that
agreement which shall continue to survive), whether oral, written or implied, heretofore in effect and sets forth the entire agreement between Conor and Distributor with respect to the subject matter hereof. 
 26. NO RIGHTS BY IMPLICATION. No rights or licenses with respect to the Products or the
Conor Intellectual Property are granted or deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement. 
 27. RESPONSIBILITY FOR TAXES. Taxes, whether in India or any other country, now or hereafter imposed with respect to the transactions contemplated hereunder (with
the exception of income taxes or other taxes imposed upon Conor and measured by the gross or net income of Conor) shall be the responsibility of Distributor, and if paid or required to be paid by Conor, the amount thereof shall be added to and
become a part of the amounts payable by Distributor hereunder. 
 28. MODIFICATION OF
PRODUCTS. Distributor may not customize, modify or have customized or modified any Product unless it obtains the prior written consent of Conor, which consent may be withheld in the sole discretion of Conor. Any unauthorized
customizing or modification of any Product by Distributor or any third party shall relieve Conor from any obligation it would otherwise have had with respect to such Product under the warranties described herein. 
 29. FORCE MAJEURE. 
 (a) No liability for damages. Neither Conor nor Distributor shall be liable in damages, or shall be subject to termination of this Agreement by the other party, for any delay or default in performing any
obligation hereunder if that delay or default is due to any 

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 16.

 
cause beyond the reasonable control and without fault or negligence of that party; provided that, in order to excuse its delay or default hereunder, a party
shall notify the other of the occurrence or the cause, specifying the nature and particulars thereof and the expected duration thereof; and provided, further, that within fifteen (15) calendar days after the termination of such occurrence or
cause, such party shall give notice to the other party specifying the date of termination thereof. All obligations of both parties shall return to being in full force and effect upon the termination of such occurrence or cause (including without
limitation any payments which became due and payable hereunder prior to the termination of such occurrence or cause). 
 (b) Cause beyond reasonable control. For the purposes of this Section, a “cause beyond the reasonable control” of a party shall include, without limiting the generality of the phrase, any act of God, act of any government
or other authority or statutory undertaking, industrial dispute, fire, explosion, accident, power failure, flood, riot or war (declared or undeclared). 
 30. COMPLIANCE WITH LAWS. Each of Distributor and Conor covenants that all of its activities under or pursuant to this Agreement shall comply with all applicable
laws, rules and regulations. In particular, but without limitation, Distributor shall assist Conor in obtaining all licenses, permits and approvals which are necessary or advisable for sales of the Products in the Territory and for the performance
of its duties hereunder, unless laws or regulations of a country in the Territory require that the Distributor obtain such licenses, permits or approvals; in that event, Distributor shall obtain the license, permit or approval. For clarity, all
licenses, permits or approvals shall be held by or in the name of Conor unless laws or regulations of a country in the Territory require that the Distributor obtain such licenses, permits or approvals, in that event, Distributor shall obtain the
licenses, permit or approval. 
 31. SEVERABILITY. If any provision of this Agreement is declared invalid or
unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement shall endure except for the part declared invalid or unenforceable by order of such court. The parties shall consult and use their best efforts to
agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid or unenforceable provision in light of the intent of this Agreement. 
 32. COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 33. PERFORMANCE BY AFFILIATES. The Parties recognize that Conor may perform some or all
of its obligations, or exercise some of all of its rights, under this Agreement through one or more of its Affiliates. Any reference to Conor in this Agreement shall be deemed to include any such Affiliates of Conor so engaged by Conor as it deems
appropriate in light of the particular facts and circumstances. 
 {SIGNATURE PAGE FOLLOWS}

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 17.

 IN WITNESS WHEREOF, the parties
hereto have signed this Agreement. 
  

							
	DISTRIBUTOR:	 	INTERNATIONAL TECHNOLOGIES LIMITED
				
		 	By:	 	/s/ V. M. Kasim	 	18/5/06
		 	Name:	 	Mr. V. M. Kasim, M.D.	 	
		 	Title:	 	M.D. & Chairman	 	
			
	CONOR:	 	CONOR MEDSYSTEMS IRELAND LTD.	 	
				
		 	By:	 	/s/ Heather Turner	 	
		 	Name:	 	Heather Turner	 	
		 	Title:	 	Director	 	
		 		 	Hamilton, Bermuda	 	4/27/06

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 18.

 EXHIBIT A 
 PRODUCT CLASS AND PRICE LIST 
  

			
	 PRODUCT
	  	PRICE (EUROS)
	 Conor cobalt chrome stent with paclitaxel
	  	[ * ]

 Company may increase Product price no more than [ * ] in any calendar
year. 
 The Product price is established in conjunction with Section 2 this agreement. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 19.

 EXHIBIT B 
 PRINCIPLE ORDERING TERMS 
 1.
V.A.T., Taxes and Duties. All prices quote exclude V.A.T., state, federal and governmental taxes and duties, and Interventional Technologies Limited (BUYER) will be liable for such taxes if applicable. 
 2. Delivery charges. All the prices, unless otherwise agreed between the parties, do not include delivery charges (prices are considered FCA
—Incoterms 2000 Conor’s Plants). RI BUYER shall specify the carrier on each purchase order. 
 3. Purchase Orders. The BUYER
shall submit purchase orders for the Products in writing which, at minimum, shall set forth: 
 (a) an identification
of the Products ordered (Conor’s catalog number); 
 (b) quantity per each product; 
 (c) requested delivery date 
 (d) any special shipping and packaging instructions; and 
 (e) shipping
address. 
 4. Acceptance and Confirmation of Orders. On receipt of an order, a detailed proforma invoice (Order Confirmation) is faxed
to the BUYER as an order acknowledgement. 
 5. Modifications of Orders. No accepted and confirmed purchase orders shall be modified or
cancelled except upon the written agreement of both parties. 
 6. Quantities Required. Products to be purchased by the BUYER must be
at least [ * ] per catalog number in order to facilitate the storage and shipping conditions of the Products. 
 7. Complete
Orders. Purchase orders are considered shipped complete when the quantity invoiced is the same as the ordered quantity. 
  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 20.

 EXHIBIT C 
 MINIMUM QUARTERLY PURCHASE ORDERS 
 (IN UNITS) 
 AGREEMENT YEAR 2006

  

							
	 Product
	  	Q2	 	Q3	 	Q4
	 Conor cobalt chrome stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]

 AGREEMENT YEAR 2007 
  

									
	 Product
	  	Q1	 	Q2	 	Q3	 	Q4
	 Conor cobalt chromium stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

 AGREEMENT YEAR 2008 
  

									
	 Product
	  	Q1	 	Q2	 	Q3	 	Q4
	 Conor cobalt chromium stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

  

	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 21.Agreement and Plan of Merger

 Exhibit 10.1 
 AGREEMENT AND PLAN OF MERGER 
 This Agreement and Plan of Merger (“Agreement”) is dated as
of August 9, 2006, between Pulaski Investment Corporation (“PIC”), a bank holding company with principal offices in Little Rock, Arkansas, and IBERIABANK Corporation (“IBKC”), a bank holding company with principal offices in
Lafayette, Louisiana. 
 RECITALS 
 1. The Board of Directors of each party hereto believes that the transactions described in this Agreement are in the best interests of such party and its stockholders. 
 2. By virtue of the reorganization that is effectuated by this Agreement, PIC will be merged with and into IBERIABANK Acquisition Corporation
(“IBAC”), a wholly-owned subsidiary of IBKC (the “Merger”), and except as provided in this Agreement, the then outstanding shares of PIC Common Stock will be converted into shares of IBKC Common Stock and cash. 
 3. The Merger is subject to prior stockholder and regulatory approvals and the prior satisfaction of certain other conditions set forth in this
Agreement. 
 4. The parties hereto intend that the reorganization contemplated by this Agreement qualify for federal income tax purposes as
a tax-free reorganization under the Internal Revenue Code of 1986, as amended. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing and of the mutual warranties, representations, covenants and agreements set forth herein, and
for other good and valuable consideration the receipt and sufficiency of which are acknowledged, the parties to this Agreement agree as follows: 
 SECTION I. 
 DEFINITIONS 
 Except as may otherwise be provided in this Agreement, the capitalized terms set forth below shall have the following respective meanings, in their singular or plural forms as applicable: 
 1.1 “Acquisition Proposal” – shall mean any tender offer or exchange offer or any proposal for a merger, acquisition of all of the
capital stock or assets of, share exchange, or other business combination involving the acquisition of PIC or any of its Subsidiaries or the acquisition of a substantial equity interest in, or a substantial portion of the assets of, PIC or any of
its Subsidiaries, or any public announcement of a proposal, plan or intention to do any of the foregoing or any agreement to engage in any of the foregoing, other than the transactions contemplated under this Agreement. 
 1.2 “Agreement” – this Agreement and Plan of Merger, including any amendment hereto. 
 1.3 “ABCA” – the Arkansas Business Corporation Act. 
 1.4 “BCL” – the Louisiana Business Corporation Law. 
 1.5 “BHC
Act” – the federal Bank Holding Company Act of 1956. 
 1.6 “Business Day” – Monday through Friday of
each week, except a legal holiday recognized as such by the U.S. Government or any day on which banking institutions in the states of Louisiana and/or Arkansas are authorized or obligated to close. 

 1.7 “Certificates” – the certificates representing shares of PIC Common Stock on or
prior to the Effective Date. 
 1.8 “Closing” – the closing of the transactions contemplated hereunder as described in
Section 3.1 of this Agreement. 
 1.9 “Code”– the Internal Revenue Code of 1986, as amended. 
 1.10 “Effective Date” – the date and time at which the Merger becomes effective, as described in Section 3.2 of this
Agreement. 
 1.11 “ERISA” – the Employee Retirement Income Security Act of 1974, as amended. 
 1.12 “Exchange Agent” – IBKC’s stock transfer agent or such other third party experienced in the stock transfer business
reasonably acceptable to PIC which shall act as the exchange agent pursuant to Section 2.2(f) hereof. 
 1.13 “Exchange
Ratios” – the Fixed Exchange Ratio and the Floating Exchange Ratio. 
 1.14 “Federal Reserve” – the Board
of Governors of the Federal Reserve System. 
 1.15 “Financial Statements” – (i) the audited consolidated balance
sheets (including related notes and schedules, if any) of a Warrantor, as of December 31, 2005 and 2004 with respect to IBKC and as of December 31, 2005 and 2004 with respect to PIC, and the related consolidated statements of income (or
statements of income and comprehensive income), changes in stockholders’ equity, and cash flows (including related notes and schedules, if any) for the respective years then ended, and (ii) the unaudited consolidated balance sheets of such
Warrantor (including related notes and schedules, if any) and related consolidated statements of income (or statements of income and comprehensive income), changes in stockholders’ equity, and cash flows (including related notes and schedules,
if any) with respect to the quarterly periods ended subsequent thereto. 
 1.16 “Fixed Exchange Ratio” - .2274 shares of
IBKC Common Stock (rounded to the nearest ten-thousandth of a share). 
 1.17 “Floating Exchange Ratio” – the quotient
(rounded to the nearest ten-thousandth of a share) obtained by dividing $13.323 by the Market Value. 
 1.18 “GAAP” –
generally accepted accounting principles in the United States of America. 
 1.19 “IBERIABANK” – IBERIABANK, a
Louisiana banking corporation and a wholly owned subsidiary of IBKC. 
 1.20 “IBAC” – IBERIABANK Acquisition
Corporation, a Louisiana corporation and a wholly owned subsidiary of IBKC. 
 1.21 “IBKC” – IBERIABANK
Corporation, a Louisiana corporation. 
 1.22 “IBKC Common Stock” – the common stock, par value $1.00 per share, of
IBKC. 
 1.23 “Market Value” – the average of the daily weighted average trading prices of the IBKC Common Stock on the
NASDAQ Global Market (as calculated by Bloomberg Screen AQR) on each of the fifteen (15) trading days ending one (1) Business Day prior to the Effective Date. 
 1.24 “Material Adverse Effect” – with respect to a Warrantor, means any change, effect, event, occurrence or state of facts that (a) is, or would reasonably be expected to be, materially
adverse to the business, financial condition or results of operations of such Warrantor and its Subsidiaries taken as a whole, or (b) materially 
  

 - 2 - 

 and adversely affects the ability of the Warrantor to perform its obligations hereunder or materially and adversely
affects the timely consummation of the transactions contemplated hereby; provided, however, that “Material Adverse Effect” shall not be deemed to include the impact of (i) any change in the value of the securities or loan portfolio of
the Warrantor, whether held as available for sale or held to maturity, resulting from changes in the prevailing level or interest rates; (ii) any change, effect, event or occurrence relating to the announcement or performance of this Agreement
and the transactions contemplated hereby, including the expenses incurred by the Warrantor in consummating the transactions contemplated by this Agreement; (iii) with respect to PIC and its Subsidiaries, any change, effect, event or occurrence
resulting from any action or omission taken with the prior consent of IBKC; (iv) any change in banking, or similar laws, rules or regulations of general applicability or interpretations thereof by courts or governmental authorities;
(v) any change in GAAP or regulatory accounting requirements applicable to banks or their holding companies generally; and (vi) the payment of any amounts due to, or the provision of any other benefits to, any directors, officers or
employees of PIC and its Subsidiaries pursuant to employment agreements, plans and other arrangements described in this Agreement. 
 1.25
“Merger” – the merger of PIC with and into IBAC. 
 1.26 “Merger Agreement” — the Merger Agreement,
substantially in the form attached hereto as Exhibit I, providing for the Merger. 
 1.27 “1933 Act” –
the Securities Act of 1933, as amended. 
 1.28 “1934 Act” – the Securities Exchange Act of 1934, as amended.

 1.29 “PBT” – Pulaski Bank & Trust Company, an Arkansas banking corporation and a wholly owned
subsidiary of PIC. 
 1.30 “PIC” – Pulaski Investment Corporation, an Arkansas corporation. 
 1.31 “PIC Common Stock” – the common stock, par value $0.25 per share, of PIC. 
 1.32 “Person” – any individual, bank, corporation, partnership, association, joint stock company, business trust, limited liability
company or unincorporated association. 
 1.33 “Proxy Statement” – the proxy or information statement to be used by PIC
and, if required by law or applicable NASDAQ listing standards, IBKC in connection with the Stockholders Meeting to consider and vote upon the transactions contemplated by this Agreement, together with any and all amendments or supplements thereto.

 1.34 “Registration Statement” – the Registration Statement on Form S-4 (or other appropriate form) and all
amendments and supplements thereto filed with the SEC by IBKC under the 1933 Act in connection with the transactions contemplated by this Agreement. 
 1.35 “Regulatory Authorities” – collectively, any federal or state banking, insurance, securities or other governmental or regulatory authority whose approval is necessary to consummate the
transactions contemplated by this Agreement. 
 1.36 “SEC”- the United States Securities and Exchange Commission.

 1.37 “SEC Documents” – all reports, proxy statements, registration statements and other documents filed by any
Warrantor pursuant to the Securities Laws. 
 1.38 “Securities Laws” – the 1933 Act, the 1934 Act, the Investment
Company Act of 1940, the Investment Advisors Act of 1940, the Trust Indenture Act of 1939, and the rules and regulations of the SEC under each of such acts. 
  

 - 3 - 

 1.39 “Stockholders Meeting” – the meeting of the stockholders of PIC and, if
required by law or applicable NASDAQ listing standards, of IBKC to be held pursuant to Section 7.1(b) of this Agreement, including any adjournments thereof. 
 1.40 “Subsidiaries” - all those corporations, banks, savings banks, associations and other entities of which the Person in question owns or controls 100% or more of the outstanding equity securities
either directly or through an unbroken chain of entities as to each of which 100% or more of the outstanding equity securities is owned directly or indirectly by such Person; provided, however, there shall not be included any such entity acquired in
good faith through foreclosure, or any such entity to the extent that the equity securities of such entity are owned or controlled in a bona fide fiduciary capacity, through a small business investment corporation or otherwise as an investment by an
entity that invests in unaffiliated companies in the ordinary course of business. 
 1.41 “Warrantor” – IBKC or PIC, as
the case may be. 
 1.42 “Warrantor Benefit Plans” – the benefit plans of IBKC or PIC, as defined in
Section 5.11(a) of this Agreement and as the context shall require, which shall depend on whether the Warrantor is IBKC or PIC and shall correspond therewith. 
 1.43 “Warrantor Common Stock” – the IBKC Common Stock or the PIC Common Stock, as the context shall require, which shall depend on whether the Warrantor is IBKC or PIC and shall correspond
therewith. 
 1.44 “Warrantor Companies” – collectively, PIC and all PIC Subsidiaries or, collectively, IBKC and
all IBKC Subsidiaries, as the context shall require. 
 1.45 “Warrantor Financial Statements” – the Financial
Statements of Warrantor. 
 1.46 “Warrantor Subsidiaries” – the Subsidiaries of PIC or IBKC, as the context shall
require, which shall include the Subsidiaries described in Section 1.40 of this Agreement and any corporation, bank, savings bank, association or other entity that becomes or is acquired as a Subsidiary of a Warrantor in the future. 

Other terms are defined as set forth below. 
 SECTION II. 
 CERTAIN TRANSACTIONS AND TERMS OF MERGER 
 2.1 Merger. Subject to the terms and conditions of this Agreement, at the Effective Date, PIC will be merged with and into IBAC in accordance with
the Merger Agreement, this Agreement, the ABCA and the BCL. 
 2.2 Conversion of PIC Common Stock. 
 (a) As used herein, the term “Total Merger Consideration” shall mean: (i) a number of shares of IBKC Common Stock with a total market value
of $32.5 million based upon the trading price of IBKC Common Stock applicable to the Fixed Exchange Ratio ($58.60 per share);plus (ii) a number of shares of IBKC Common Stock with a total Market Value of $32.5 million based upon the trading
prices of IBKC Common Stock to be applicable to the Floating Exchange Ratio; plus (iii) cash (without interest) in the total amount of $65.0 million, subject to adjustment under Sections 7.8 and 8.7 of this Agreement. 
  

 - 4 - 

 (b) Except for shares of PIC Common Stock as to which dissenters’ rights have been perfected and not
withdrawn or otherwise forfeited (“Dissenters’ Shares”) under the ABCA, and as otherwise provided herein, at the Effective Date each issued and outstanding share of PIC Common Stock will be converted into the “ Per Share Merger
Consideration” which shall mean: 
  

	 	(i)	shares of IBKC Common Stock based upon the Fixed Exchange Ratio; plus 

  

	 	(ii)	shares of IBKC Common Stock based upon the Floating Exchange Ratio; plus 

  

	 	(iii)	an amount of cash (without interest) determined by dividing $65.0 million by the number of shares of PIC Common Stock outstanding on the Effective Date (rounded to the nearest whole
cent). 

 (c) Shares of PIC Common Stock that are held by PIC and any PIC Subsidiary (other than shares held in a fiduciary
capacity) shall not be considered to be outstanding and shall be cancelled (and not converted) by virtue of the Merger at the Effective Date and without any further action by any party. 
 (d) If, before the Effective Date, IBKC should split, reclassify, recapitalize or combine the IBKC Common Stock, or pay a stock dividend in IBKC Common
Stock, or otherwise change the IBKC Common Stock into any other securities, or make any other dividend or distribution in respect of the IBKC Common Stock (other than normal cash dividends consistent with past practices as the same may be adjusted
from time to time in accordance with or not in violation of this Agreement), and the record date therefore is prior to the Effective Date, then the Exchange Ratios will be appropriately and proportionately adjusted to reflect such split,
reclassification, recapitalization, combination, stock dividend or other distribution or change. 
 (e) In lieu of issuing any fractional
share of IBKC Common Stock which would otherwise be distributable to a PIC stockholder as determined following application of Section 2.2(a), each holder of PIC Common Stock who would otherwise be entitled thereto, after aggregating into whole
shares all fractional shares of IBKC Common Stock to which such holder is entitled by virtue of the Merger, upon surrender of the certificate(s) which represented PIC Common Stock, will receive, without interest, cash equal to such fractional share
multiplied by $58.60. 
 (f) No later than the Effective Date, IBKC shall deposit, or shall cause to be deposited, with the Exchange Agent
for the benefit of the holders of PIC Common Stock, for exchange in accordance with this Section 2.2, certificates and cash (in immediately available funds) representing the Total Merger Consideration to be paid. After the Effective Date, each
holder of PIC Common Stock (other than Dissenters’ Shares), upon surrender of such holder’s Certificates in accordance herewith, will be entitled to receive the shares of IBKC Common Stock and cash into which such holder’s shares have
been converted, less any applicable tax withholding. Until then, each Certificate for PIC Common Stock will represent the Per Share Merger Consideration into which the shares of PIC Common Stock represented thereby were converted, except that IBKC
may refuse to pay any dividend or other distribution payable to holders of any unsurrendered Certificate for PIC Common Stock (without any interest thereon) until surrender or if such dividend or distribution has reverted in full ownership to IBKC
under its Articles of Incorporation. Whether or not a Certificate for PIC Common Stock is surrendered, after the Effective Date it will not represent any interest in any Person other than IBKC. 
 (g) Prior to the Effective Date, IBKC or the Exchange Agent shall mail to each holder of record of a Certificate or Certificates a form of letter of
transmittal (which shall specify that delivery shall be effected, and risk of loss and title to the Certificates shall pass, only upon delivery of the Certificates to the Exchange Agent) and instructions for use in effecting the surrender of the
Certificates in exchange for the Per Share Merger Consideration into which the shares of PIC Common Stock represented by such Certificate or Certificates shall have been converted pursuant to this Section 2.2. Upon proper surrender of a
Certificate for exchange and cancellation to the Exchange Agent, together with a properly completed letter of transmittal, duly executed, the holder of such Certificate shall be entitled to receive in exchange therefore (i) a certificate
representing that number of shares of IBKC Common Stock to which such former holder of PIC Common Stock shall have become entitled pursuant to this Agreement and (ii) a check (or, as provided in Section 2.2(h) below, wire transfer of
immediately available funds) representing that amount of cash to which such former holder of PIC Common Stock shall have become entitled pursuant to this Agreement. 
  

 - 5 - 

 (h) IBKC and the Exchange Agent shall within one (1) Business Day after the Effective Date wire the
cash amount of the Per Share Merger Consideration and deliver by overnight courier certificates for shares of IBKC Common Stock to any former holders of PIC Common Stock who request such payment and have properly surrendered Certificates in exchange
for the Merger Consideration prior to the Effective Date. 
 (i) In the event any Certificate shall have been lost, stolen or destroyed, upon
the making of an affidavit of that fact by the person claiming such Certificate to be lost, stolen or destroyed and the posting by such person of a bond in such amount as IBKC may reasonably direct as indemnity against any claim that may be made
against it with respect to such Certificate, the Exchange Agent will issue in exchange for such lost, stolen or destroyed Certificate the Per Share Merger Consideration deliverable in respect thereof. 
 (j) If the Person surrendering a Certificate and signing the accompanying letter of transmittal is not the record holder thereof, then it shall be a
condition of the payment of the Per Share Merger Consideration that: (i) such Certificate is properly endorsed to such Person or is accompanied by appropriate stock powers, in either case signed exactly as the name of the record holder appears
on such Certificate, and is otherwise in proper form for transfer, or is accompanied by appropriate evidence of the authority of the Person surrendering such Certificate and signing the letter of transmittal to do so on behalf of the record holder;
and (ii) the person requesting such exchange shall pay to the Exchange Agent in advance any transfer or other similar taxes required by reason of the payment to a Person other than the registered holder of the Certificate surrendered, or
required for any other reason, or shall establish to the satisfaction of the Exchange Agent that such tax has been paid or is not payable. 
 2.3 Employee Agreements. 
 (a) Schedule 2.3(a) sets forth a list of all of the Executive Phantom Ownership Plan
Agreements, Deferred Compensation Agreements and Retention Agreements (collectively, the “Agreements”) between PIC or its applicable Subsidiary and their respective employees and the estimated amounts to be paid by PIC or its applicable
Subsidiary, at or immediately prior to the Effective Date, to the employees as set forth on Schedule 2.3(a) pursuant to said Agreements. At or prior to the Effective Date, PIC or its applicable Subsidiary shall pay to the employees listed on
Schedule 2.3(a) the amounts, without material deviation, as set forth on Schedule 2.3(a) against delivery by each listed employee of an instrument in writing signed by the employee acknowledging (i) receipt of said payment as full
payment for all amounts due and payable to such employee thereunder and (ii) the termination of said agreement, effective immediately upon the execution and delivery of said acknowledgment. In addition, at or prior to the Effective Date, PIC
and its applicable Subsidiaries shall terminate the Executive Phantom Ownership Plan and Deferred Compensation Plan under which such Agreements were executed. 
 (b) Schedule 2.3(b) sets forth a list of all of the Stay Agreements which PIC has or expects to enter between PIC (or its applicable Subsidiary) and their respective employees. 
 SECTION III. 
 CLOSING AND EFFECTIVE
DATE 
 3.1 Time and Place of Closing. 
 (a) The Closing will take place on a mutually agreed upon Business Day within twenty-one (21) days, or such lesser number of days as is reasonably practical, subsequent to the last of (i) the date of receipt
of all required federal or state regulatory agency approvals of the Merger and the expiration of all required waiting periods, and (ii) the date on which the stockholders of PIC approve this Agreement at the Stockholders Meeting to be held
pursuant to Section 7.1(b) of this Agreement; or such other date as the parties hereto may mutually agree. If all conditions in Section VIII hereof are satisfied, or waived by the party entitled to grant such waiver, at the Closing (i) the
parties shall each provide to the others such proof of satisfaction of the conditions in Section VIII as the party whose obligations are conditioned upon such satisfaction may reasonably request, (ii) the certificates, letters and opinions
required by Section VIII shall be delivered, (iii) the directors and appropriate officers of the parties shall authorize, execute, deliver and acknowledge the articles and certificate of merger, and (iv) the parties shall take such further
action, including (without limitation) filing the Merger Agreement and any other necessary filings with the Secretary of State of Louisiana and necessary filings with the Secretary of State of Arkansas, to consummate the transactions contemplated by
this Agreement. 
  

 - 6 - 

 (b) If on any date established for the Closing all conditions in Section VIII hereof have not been
satisfied or waived by each Warrantor entitled to grant such waiver, then either Warrantor, on one or more occasions, may declare a delay of the Closing of such duration, not exceeding ten (10) days, as the declaring Warrantor shall select, but
no such delay shall extend beyond the last date set forth in subparagraph (c) of Section 9.1(c), and no such delay shall interfere with the right of either Warrantor to declare a termination pursuant to Section IX. The place of Closing
shall be at the office of IBKC set forth in Section 10.7. 
 3.2 Effective Date. Subject to the satisfaction or waiver of
the conditions set forth in Article VIII, the Merger shall become effective upon the approval of the Merger by the Board of Governors of the Federal Reserve System and necessary filings with the Louisiana Secretary of State in accordance with the
BCL and the Arkansas Secretary of State in accordance with the ABCA, or such later date and time or may be set forth in such filings (the time the Merger becomes effective being referred to as the “Effective Date.”). 
 SECTION IV. 
 MANAGEMENT AND RELATED
MATTERS FOLLOWING MERGER 
 4.1 Board of Directors and Officers of IBAC. At the Effective Date, the board of directors and
officers of IBAC shall consist of those persons serving as directors and officers of IBKC immediately prior to the Effective Date. 
 4.2 Board of Directors and Officers of PIC Subsidiaries. At the Effective Date, the directors and officers of the PIC Subsidiaries shall consist of those persons designated by IBKC prior to the Effective Date. 
 4.3 Employees and Benefits. 
 (a) The
employees of PIC and its Subsidiaries who remain employed after the Effective Date (“Continuing Employees”) shall be given credit under each employee benefit plan, policy, program and arrangement maintained by IBERIABANK after the Closing
for their service with PIC or its Subsidiary prior to the Closing for all purposes, including severance, vacation and sick leave, eligibility to participate, vesting, satisfying any waiting periods, evidence of insurability requirements, seniority
or the application of any pre-existing condition limitations, other than benefit accrual under a defined benefit plan (as defined in Section 3(35) of ERISA); provided, however, that accrued vacation taken subsequent to the Effective Date may be
subject to such limitations as IBKC or IBERIABANK may reasonably require. Any employee of PIC or its Subsidiaries who does not remain employed by PIC or its Subsidiaries after the Effective Date or does not receive a severance payment in connection
with the Merger shall receive a severance payment as if he or she were an employee of IBKC for the entire time he or she were an employee of PIC. 
 (b) In the event of any termination of any PIC or PIC Subsidiary health plan (collectively, a “PIC health plan”), IBKC and IBERIABANK shall make available to Continuing Employees and their dependents, employer-provided health care
coverage under health plans provided by IBKC and IBERIABANK. Unless a Continuing Employee affirmatively terminates coverage under a PIC health plan prior to the time that such Continuing Employee becomes eligible to participate in the IBKC health
plan, no coverage of any of the Continuing Employees or their dependents shall terminate under any of the PIC health plans prior to the time such Continuing Employees and their dependents become eligible to participate in the health plans, programs
and benefits common to all employees and their dependents of IBKC and IBERIABANK. In the event IBKC terminates any PIC health plan or consolidates of any PIC health plan with any IBKC health plan, individuals covered by the PIC health plan shall be
entitled to immediate coverage under the IBKC health plan in accordance with the Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations issued thereunder, including limitations on pre-existing condition
exclusions, nondiscrimination and special enrollment rights. All PIC employees who cease participating in a PIC health plan and become participants in a comparable IBKC health plan shall receive credit for any co-payment and deductibles paid under
PIC’s health plan, to the extent such credit would be provided under PIC’s health plan, for purposes of satisfying any applicable deductible or out-of-pocket requirements under the IBKC health plan, upon substantiation, in a form
reasonably satisfactory to IBKC, that such co-payment and/or deductible has been satisfied. 
  

 - 7 - 

 4.4 Indemnification and Insurance. 
 (a) IBKC agrees that all rights to indemnification and all limitations of liability existing in favor of any director or officer of PIC or any PIC
Subsidiary (the “Indemnified Parties”) as provided in PIC’s or the PIC Subsidiary’s articles of incorporation or bylaws (including without limitation the right to the advancement of expenses) with respect to matters occurring on
or prior to the Effective Date shall survive the Merger and shall continue in full force and effect, without any amendment thereto, for a period of six (6) years from the Effective Date; provided, however, that all rights to
indemnification in respect of any claim, suit, proceeding, investigation, or other action (“Claim”) asserted or made within such period shall continue until the final disposition of such Claim; provided further, however, that
nothing contained in this Section 4.4(a) shall be deemed to preclude the liquidation, consolidation or merger of PIC or any PIC Subsidiary, in which case all of such rights to indemnification and limitations on liability shall be deemed to so
survive and continue notwithstanding any such liquidation, consolidation or merger and shall constitute rights which may be asserted against IBKC. Nothing contained in this Section 4.4(a) shall be deemed to preclude any rights to
indemnification or limitations on liability provided in PIC’s or any PIC Subsidiary’s articles of incorporation with respect to matters occurring subsequent to the Effective Date to the extent that the provisions establishing such rights
or limitations are not otherwise amended to the contrary. 
 (b) Any Indemnified Party wishing to claim indemnification under
Section 4.4, upon learning of any claim, shall notify IBKC thereof in writing as promptly as is practicable; provided, however, that failure to so notify IBKC shall not relieve IBKC from any liability that would otherwise arise under this
Section 4.4 except to the extent such failure prejudices IBKC. IBKC shall have the right to assume the defense thereof and shall not be liable for any expenses subsequently incurred by such Indemnified Party in connection with the defense
thereof, except that if IBKC does not assume or continue to pursue such defense, or counsel for the Indemnified Party advises in writing that issues raise conflicts of interest between IBKC and the Indemnified Party, then the Indemnified Party may
retain counsel satisfactory to such Indemnified Party (and reasonably satisfactory to IBKC) at IBKC’s expense; provided, however, that (i) IBKC shall not be obligated to pay for more than one counsel for all Indemnified Parties in any
jurisdiction except as may be required due to conflicts of interest; (ii) the Indemnified Parties will cooperate (to the extent reasonably appropriate under the circumstances) in the defense of any such claim; and (iii) IBKC shall not be
liable for any settlement effected without the prior written consent of IBKC, which consent may be withheld unless such settlement is reasonable in light of such claims, actions, suits, proceedings or investigations against, and defenses available
to, such Indemnified Party. 
 (c) PIC will, for total premiums not to exceed $161,000 (the “Maximum Amount”), purchase a
continuation of their current directors and officers liability insurance for a coverage period of three (3) years after the Merger, provided that if the amount of the annual premiums necessary to maintain or procure such insurance coverage
exceeds the Maximum Amount, IBKC shall maintain the most advantageous policies of directors’ and officers’ insurance obtainable for an annual premium equal to the Maximum Amount. 
 (d) If IBKC or any of its successors or assigns (i) reorganizes or consolidates with or merges into or enters into another business combination
transaction with any other Person or entity and is not the resulting, continuing or surviving corporation or entity of such reorganization, consolidation, merger or transaction or (ii) liquidates, dissolves or transfers all or substantially all
of its properties and assets to any Person or entity, then, and in each such case, proper provisions will be made so that such surviving corporation or transferee and its successors and assigns assume the obligations of IBKC set forth in this
Agreement. The obligations of IBKC under this Section 4.4 are intended to be for the benefit of, and enforceable against IBKC directly by, the Indemnified Parties and their heirs and representatives and shall be binding on all respective
successors and permitted assigns of IBKC. IBKC shall pay all reasonable costs, including attorneys’ fees, that may be incurred by any Indemnified Party in successfully enforcing the indemnity and other obligations provided for in this
Section 4.4 to the fullest extent permitted under applicable law. The rights of each Indemnified Party hereunder shall be in addition to any other rights such Indemnified Party may have under applicable law. The provisions of this
Section 4.4 shall survive the Effective Date. 
  

 - 8 - 

 SECTION V. 
 REPRESENTATIONS AND WARRANTIES OF IBKC AND PIC 
 IBKC and PIC hereby represent and warrant to the
other Warrantor, to the extent pertaining to itself, its Subsidiaries, and/or its business or affairs, subject to the standard set forth in Section 5.21 hereof, that: 
 5.1 Organization, Standing, and Authority. Warrantor is a corporation duly organized, validly existing, and in good standing under the laws of the state of its incorporation, and is duly qualified to do
business and in good standing in the states of the United States and foreign jurisdictions where its ownership or leasing of property or the conduct of its business requires it to be so qualified, except where the failure to be so qualified or in
good standing would not have a Material Adverse Effect. Warrantor has corporate power and authority to carry on its business as now conducted in all material respects, to own, lease and operate its assets, properties and business, and to execute and
deliver, and to perform its obligations under, this Agreement. Warrantor is duly registered with the Federal Reserve as a bank holding company under the BHC Act. Warrantor has in effect all federal, state, local and foreign governmental
authorizations necessary for it to own or lease its properties and assets and to carry on its business as it is now conducted in all material respects. Each of IBERIABANK and PBT is an “insured depository institution” as defined in the
Federal Deposit Insurance Act and applicable regulations thereunder. 
 5.2 Capital Stock. 
 (a) The authorized, issued and outstanding capital stock of Warrantor as of the date of this Agreement, the number of shares of Warrantor Common Stock
reserved for issuance under the Warrantor Benefit Plans as of such date and the number of shares of Warrantor Common Stock that are subject to outstanding stock options under such Warrantor Benefit Plans as of such date, are set forth in Schedule
5.2(a) that pertains to Warrantor. All of the issued and outstanding shares of capital stock of Warrantor are duly and validly authorized and issued and are fully paid and non-assessable. None of the outstanding shares of the capital stock of
Warrantor has been issued in violation of any preemptive rights of the current or past stockholders of Warrantor. All of the IBKC Common Stock to be issued in exchange for PIC Common Stock upon consummation of the Merger, when issued in accordance
with the terms of this Agreement, will be duly and validly authorized and fully paid and non-assessable. 
 (b) Except as set forth in
Section 5.2(a), Section 6.1(e) or Schedule 5.2(a), there are, as of the date of this Agreement and will be, at the Effective Date, no shares of capital stock or other equity securities of PIC outstanding and no outstanding options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, shares of the capital stock of PIC or contracts, commitments, understandings or
arrangements by which PIC is or may be bound to issue additional shares of its capital stock or options, warrants or rights to purchase or acquire any additional shares of its capital stock. 
 5.3 Subsidiaries. Schedule 5.3 lists all of the Subsidiaries of Warrantor as of the date of this Agreement. Except as provided in
Louisiana Revised Statutes 6:262, all of the shares of capital stock of IBERIABANK held by IBKC are fully paid and non-assessable and are owned by IBKC free and clear of any claim, lien or encumbrance. Each Subsidiary of Warrantor is a corporation
duly organized, validly existing and in good standing under the laws of the state of its incorporation, and is duly qualified to do business and in good standing in the jurisdictions where its ownership or leasing of property or the conduct of its
business requires it to be so qualified, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect. Each of PBT and IBERIABANK has the corporate power and authority necessary for it to own or lease its
properties and assets and to carry on its business as it is now being conducted, and has all federal, state, local and foreign governmental authorizations necessary for it to own or lease its properties and assets and to carry on its business as it
is now being conducted in all material respects. 
 5.4 Authority. 
 (a) The execution and delivery of this Agreement and the consummation of the transactions contemplated herein or therein, including the Merger, have been
duly and validly authorized by all necessary 
  

 - 9 - 

 corporate action on the part of Warrantor, subject, with respect to this Agreement, to the approval of the stockholders
of PIC and, if necessary, IBKC at the Stockholders Meeting to the extent required by applicable law. This Agreement, subject to any requisite approval by PIC’s and, if necessary, IBKC’s stockholders, represents the valid and legally
binding obligation of Warrantor, enforceable against Warrantor, in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting the
enforcement of creditors’ rights generally and except that the availability of the equitable remedy of specific performance or injunctive relief is subject to the discretion of the court before which any proceeding may be brought. 

(b) Neither the execution and delivery of this Agreement by Warrantor, nor the consummation by Warrantor of the transactions contemplated herein or
therein, nor compliance by Warrantor with any of the provisions hereof or thereof, will (i) conflict with or result in a breach of any provision of the charter or by-laws of IBKC or PIC, or (ii) except as set forth on Schedule
5.4(b), constitute or result in the breach of any term, condition or provision of, or constitute a default under, or give rise to any right of termination, cancellation or acceleration with respect to, or result in the creation of any lien,
charge or encumbrance upon any property or assets of Warrantor, pursuant to, any note, bond, mortgage, indenture, license, agreement, lease or other instrument or obligation to which any of them is a party or by which any of them or any of their
properties or assets may be subject, except such as individually or in the aggregate will not have a Material Adverse Effect, or (iii) subject to receipt of the requisite approvals, authorizations, filings, registrations and notifications
referred to in Section 8.5 of this Agreement, violate any order, writ, injunction, decree, statute, rule or regulation applicable to Warrantor, or any of its properties or assets. 
 (c) Other than in connection or compliance with the provisions of applicable state corporate and securities laws, the Securities Laws and the rules and
regulations thereunder, and other than consents, authorizations, approvals or exemptions required from Regulatory Authorities, no notice to, filing with, authorization of, exemption by or consent or approval of any public body or authority is
necessary for the consummation by Warrantor of the Merger and the other transactions contemplated by this Agreement. 
 (d) The Board of
Directors of each of the parties hereto (at a meeting duly called and held prior to the execution of this Agreement) has by requisite vote (i) determined that the Merger is in the best interests of such party and its stockholders,
(ii) authorized and approved this Agreement and the transactions contemplated hereby, including the Merger, and (iii) directed that the Merger be submitted for consideration to PIC’s stockholders and, if necessary, IBKC’s
stockholders at the Stockholders Meeting. 
 5.5 Financial Statements; Accounting. Prior to the execution of this Agreement,
each Warrantor has delivered to the other Warrantor its Warrantor Financial Statements through the period ended December 31, 2005, and each Warrantor will promptly deliver when available copies of such Warrantor Financial Statements in
respect of periods ending after December 31, 2005. Each of the Warrantor Financial Statements (as of the dates thereof and for the periods covered thereby): (i) is (and, in the case of Warrantor Financial Statements in respect of periods
ending after December 31, 2005, will be) in accordance with the books and records of the Warrantor, and have been and will continue to be maintained in accordance with GAAP (except as permitted by Regulation S-X of the SEC), in all material
respects, and (ii) except as permitted by Regulation S-X of the SEC, presents (and, in the case of Warrantor Financial Statements in respect of periods ending after December 31, 2005, will present) fairly in all material respects the
consolidated financial position and the consolidated results of operations, changes in stockholders’ equity and cash flows of the Warrantor as of the dates and for the periods indicated, in all material respects in accordance with GAAP
applicable to financial institution holding companies applied on a basis consistent with prior periods, except as otherwise described (subject in the case of interim financial statements to normal year-end adjustments and the absence of footnotes).

 5.6 Absence of Undisclosed Liabilities. Except as set forth in Schedule 5.6, neither Warrantor has any obligation or
liability (contingent or otherwise) that is material, either individually or in the aggregate, to the financial condition, results of operations or, to the Warrantor’s knowledge, business prospects of the Warrantor on a consolidated basis, or
that when combined with all similar obligations or liabilities would, either individually or in the aggregate, be material to the financial condition, results of operations or, to the Warrantor’s knowledge, business prospects of the Warrantor
on a consolidated basis, except (i) as reflected in the Warrantor Financial Statements delivered prior to the date of this Agreement, (ii) as reflected by this Agreement, or (iii) for commitments and obligations made, or liabilities
incurred, since December 31, 2005, in the ordinary course of its business consistent with past practices. 
  

 - 10 - 

 5.7 Tax Matters. 
 (a) All material federal, state, local and foreign tax returns required to be filed by or on behalf of Warrantor have been timely filed or requests for
extensions have been timely filed, granted and have not expired. All taxes shown on filed returns have been paid, except for taxes which are being contested in good faith or have not yet been fully determined. There is no audit examination,
deficiency, refund litigation or matter in controversy with respect to any taxes, except as reserved against in the Warrantor Financial Statements or as set forth on Schedule 5.7(a). All taxes, interest, additions and penalties which are
material in amount and which are due with respect to completed and settled examinations or concluded litigation have been paid or adequately reserved for. 
 (b) Except as set forth on Schedule 5.7(b), Warrantor has not executed an extension or waiver of any statute of limitations on the assessment or collection of any tax due that is currently in effect.

 (c) Adequate provision for any federal, state, local or foreign taxes due or to become due for Warrantor for any period or periods through
and including December 31, 2005 has been made and is reflected in the Warrantor Financial Statements, and will be made through and including the Closing. 
 (d) Deferred taxes of the Warrantor Companies have been provided for in accordance with GAAP. 
 5.8
Loans, Reserves, and Investments. 
 (a) All loans (including discounts) and financing leases in which Warrantor is lessor (collectively,
“Credits”) reflected in the Warrantor Financial Statements were (i) made for adequate consideration in the ordinary course of business, (ii) evidenced by instruments that were true and genuine, and (iii) if secured, secured
by valid perfected security interests. An accurate trial balance of all such Credits of PIC and of the investment portfolio as of June 30, 2006 has been previously delivered to IBKC. 
 (b) The aggregate allowances for losses on Credits and other real estate and foreclosed assets owned reflected on the latest Warrantor Financial
Statement delivered on or prior to the date of this Agreement were, as of the date of such Financial Statements and will be, at the Closing, adequate, as of the respective dates of the Financial Statements, in accordance with regulatory guidelines
and GAAP in all material respects. 
 5.9 Properties and Insurance. Except as set forth on Schedule 5.9 or as reserved against
in the Warrantor Financial Statements, Warrantor, has good and, as to real property, marketable title, free and clear of all material liens, encumbrances, charges or defaults of any character, to all of the material properties and assets, tangible
or intangible, reflected in the Warrantor Financial Statements as being owned by the Warrantor as of the dates thereof. To the knowledge of Warrantor’s management, (i) all buildings and all fixtures, equipment and other property and assets
which are material to its business on a consolidated basis and are held under leases or subleases by the Warrantor are held under valid leases or subleases enforceable in accordance with their respective terms (except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting the enforcement of creditors’ rights generally and except that the availability of the equitable remedy of specific performance or injunctive
relief is subject to the discretion of the court before which any proceedings may be brought); and (ii) the policies of fire, theft, liability, fidelity and other insurance maintained with respect to the assets or businesses of the Warrantor
provide adequate coverage against loss. 
 5.10 Compliance with Laws. Except as set forth in Schedule 5.10, each
Warrantor: 
 (a) Is, to its knowledge, in compliance in all material respects with all laws, regulations, reporting and licensing
requirements and orders applicable to its business or to the employees conducting its business; 
 (b) Has received no notification or
communication from any Regulatory Authority (i) threatening to revoke any license, franchise, permit or governmental authorization which is material, either individually or in the aggregate, to the financial condition, results of operations or,
to the Warrantor’s knowledge, business prospects of 
  

 - 11 - 

 the Warrantor on a consolidated basis or the ability of the Warrantor to consummate the transactions contemplated under
this Agreement, under the terms hereof and thereof, or (ii) requiring Warrantor (or any of its officers, directors or controlling Persons) to enter into a cease and desist order, agreement or memorandum of understanding (or requiring the board
of directors thereof to adopt any resolution or policy); and 
 (c) Has complied in all material respects with the Community Reinvestment Act
(“CRA”) and the rules and regulations thereunder, and has a CRA rating of not less than “satisfactory”. 
 5.11
Employee Benefit Plans. 
 (a) (i) Warrantor has delivered or made available to the other Warrantor, prior to the execution of this
Agreement, copies of each pension, retirement, profit sharing, supplemental or excess retirement, stock option, stock purchase, savings, employee stock ownership, restricted stock, phantom stock, stock ownership, life insurance, disability, vacation
pay, severance pay (including, without limitation change of control or golden parachute arrangements), incentive, deferred compensation, bonus or benefit arrangement, health or hospitalization program, fringe benefit or perquisite arrangement or
other similar plan as in effect on the date of this Agreement, including, without limitation, any “employee benefit plan”, as that term is defined in Section 3(3) of ERISA, in respect of any of the present or former directors,
officers, other employees or independent contractors of, or dependents, spouses or other beneficiaries of any of such directors, officers, other employees or independent contractors of, any of the Warrantor Companies (collectively, the
“Warrantor Benefit Plans”), and (ii) PIC and the PIC Subsidiaries have delivered or made available to IBKC, prior to the execution of this Agreement, copies of each employment or consulting agreement as in effect on the date of this
Agreement which provides any benefit or perquisites to or in respect of any of the present or former directors or officers of, or dependents, spouses or other beneficiaries of any of such directors or officers of, PIC and the PIC Subsidiaries, which
employment and consulting agreements are, with respect to PIC and the PIC Subsidiaries, included in the term “Warrantor Benefit Plans” as defined above. Any of the Warrantor Benefit Plans which is an “employee pension benefit
plan,” as that term is defined in Section 3(2) of ERISA, is referred to herein as a “Warrantor ERISA Plan”. No Warrantor has participated in or been a member of, and no Warrantor Benefit Plan is or has been, a multi-employer plan
within the meaning of Section 3(37) of ERISA. Except as set forth on Schedule 5.11(a), the Warrantor Benefit Plans of PIC and the PIC Subsidiaries are terminable on their terms without penalty or payment except for accrued and vested
benefits thereunder. 
 (b) All Warrantor Benefit Plans comply in all material respects with the applicable provisions of ERISA and the Code,
and any other applicable laws, rules and regulations the breach or violation of which could result in a liability, either individually or in the aggregate, material to the financial condition, results of operations or prospects of the Warrantor on a
consolidated basis. With respect to the Warrantor Benefit Plans, no event has occurred and, to the knowledge of Warrantor’s management, there exists no condition or set of circumstances, in connection with which the Warrantor could be subject
to any liability (except liability for severance payments, benefit claims, Pension Benefit Guaranty Corporation premiums, and funding obligations payable in the ordinary course). No notice of a “reportable event,” as that term is defined
in Section 4043 of ERISA, for which the 30-day reporting requirement has not been waived has been required to be filed for any Warrantor ERISA Plan which is subject to Title IV of ERISA within the 12-month period ending on the date of this
Agreement. No Warrantor has provided, or is required to provide, security to any Warrantor ERISA Plan which is subject to Title IV of ERISA pursuant to Section 401(a)(20) of the Code. 
 (c) Except as set forth on Schedule 5.11(c), no Warrantor ERISA Plan which is subject to Title IV of ERISA has any “unfunded current
liability,” as that term is defined in Section 302(d)(8)(A) of ERISA, and the present fair market value of the assets of each such plan exceeds the plan’s “benefit liabilities”, as that term is defined in
Section 4001(a)(16) of ERISA, when determined under actuarial factors that would apply if the plan terminated as of the date of this Agreement in accordance with all applicable legal requirements. 
 5.12 Material Contracts. Except as set forth on Schedule 5.12, none of the Warrantor Companies, nor any of their respective assets,
businesses or operations, as of the date of this Agreement, is a party to, or is bound or affected by, or receives benefits under, any contract or agreement or amendment thereto that in each case would be required to be filed as an exhibit to a Form
10-K filed by Warrantor as of the date of this Agreement and that was not so filed (each such contract, agreement or amendment, a “Warrantor Material Contract”). No Warrantor Company is in default in any material respect under any
Warrantor Material Contract, and there has not occurred any event that, with the lapse of time or the giving of notice or both, would constitute such a default. 
  

 - 12 - 

 5.13 Legal Proceedings. Except as set forth on Schedule 5.13, there are no actions,
suits or proceedings instituted or pending or, to the knowledge of Warrantor’s management, threatened against a Warrantor Company, or affecting any property, asset, interest or right of any of them. 
 5.14 Absence of Certain Changes or Events. Since December 31, 2005, the Warrantor Companies, taken as a whole on a consolidated basis,
have not suffered any change in any respect that has had or is reasonably likely to have a Material Adverse Effect. 
 5.15
Reports. Since December 31, 2002, each of the Warrantor Companies has filed all reports and statements, together with any amendments required to be made with respect thereto, that it was required to file with (i) the SEC, including,
but not limited to, Forms 10-K, Forms 10-Q, Forms 8-K and proxy statements, (ii) the Federal Reserve, (iii) the Federal Deposit Insurance Corporation, and (iv) any applicable state banking, insurance, securities or other regulatory
authorities. As of their respective dates (and without giving effect to any amendments or modifications filed after the date of this Agreement with respect to reports and documents filed before the date of this Agreement), each of such reports and
documents, including the financial statements, exhibits and schedules thereto, complied in all material respects with all of the statutes, rules and regulations enforced or promulgated by the authority with which they were filed and did not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein in light of the circumstances under which they were made not misleading. 
 5.16 Statements True and Correct. None of the information supplied or to be supplied by Warrantor for inclusion in (i) the Registration
Statement, (ii) the Proxy Statement, and (iii) any other documents to be filed with the SEC or any other Regulatory Authority in connection with the transactions contemplated hereby, will, at the respective times such documents are filed,
and, in the case of the Registration Statement, when it becomes effective and, with respect to the Proxy Statement, when first mailed to the stockholders of PIC and, if required by law or applicable NASDAQ listing standards, IBKC, be false or
misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements therein not misleading, or, in the case of the Proxy Statement or any amendment thereof or supplement thereto, at the time of
the Stockholders Meeting, be false or misleading with respect to any material fact, or omit to state any material fact necessary to make the statements therein in light of the circumstances under which they were made not misleading. All documents
that Warrantor is responsible for filing with the SEC or any other Regulatory Authority in connection with the transactions contemplated hereby will comply in all material respects with the provisions of applicable law including applicable
provisions of the Securities Laws. 
 5.17 Environmental Matters. 
 (a) To the knowledge of Warrantor’s management, Warrantor and each Warrantor Subsidiary (for purposes of this Section 5.17, the term
“Warrantor Subsidiary” shall include small business investment corporations and entities that invest in unaffiliated companies in the ordinary course of business in which Warrantor owns or controls 5% or more of the outstanding equity
securities either directly or through an unbroken chain of entities as to each of which 5% or more of the outstanding equity securities is owned directly or indirectly by Warrantor), except as set forth in Schedule 5.17(a), the Participation
Facilities, the Loan Properties and the Trust Properties (each as defined below) are, and have been, in compliance with all applicable laws, rules, regulations and standards, and all requirements of the United States Environmental Protection Agency
(“EPA”) and of state and local agencies with jurisdiction over pollution or protection of health or the environment. 
 (b) To the
knowledge of Warrantor’s management, except as set forth in Schedule 5.17(b), there is no suit, claim, action or proceeding, pending or threatened, before any court, governmental agency, board or other forum pursuant to which Warrantor
or any of the Warrantor Subsidiaries or any Loan Property, Participation Facility or Trust Property (or in respect of such Loan Property, Participation Facility or Trust Property) has been or, with respect to threatened proceedings may be, named as
a defendant (i) for alleged noncompliance (including by any predecessor) with any environmental law, rule or regulation or (ii) relating to the release into the environment of any Hazardous Material (as defined below) or oil, whether or
not occurring at or on any site owned (including as trustee), leased or operated by it or any of its subsidiaries or any Loan Property, Participation Facility or Trust Property. 
  

 - 13 - 

 (c) To the knowledge of Warrantor’s management, except as set forth in Schedule 5.17(c),
there is no reasonable basis for any suit, claim, action or proceeding of a type described in Section 5.17(b). 
 (d) During the period
of (i) Warrantor’s or any of the Warrantor Subsidiaries’ ownership (including as trustee) or operation of any of their respective current properties, (ii) Warrantor’s or any of the Warrantor Subsidiaries’ participation
in the management of any Participation Facility, (iii) Warrantor’s or any of the Warrantor Subsidiaries’ holding of a security interest in a Loan Property, or (iv) Warrantor or any of the Warrantor Subsidiaries acting as a
trustee or fiduciary with respect to a Trust Property, to the knowledge of Warrantor’s management, there has been no release of Hazardous Material or oil in, on, under or affecting such property, Participation Facility, Loan Property or Trust
Property. Prior to the period of (w) Warrantor’s or any of the Warrantor Subsidiaries’ ownership (including as trustee) or operation of any of their respective current properties, (x) Warrantor’s or any of the Warrantor
Subsidiaries’ participation in the management of any Participation Facility, (y) Warrantor’s or any of the Warrantor Subsidiaries acting as trustee or other fiduciary with respect to Trust Property, or (z) Warrantor’s or any
of the Warrantor Subsidiaries’ holding of a security interest in a Loan Property, to the knowledge of Warrantor’s management, there was no release of Hazardous Material or oil in, on, under or affecting any such property, Participation
Facility, Loan Property or Trust Property. 
 (e) The following definitions apply for purposes of this Section 5.17: (i) “Loan
Property” means any property in which Warrantor (or a Warrantor Subsidiary) holds a security interest and, where required by the context, includes the owner or operator of such property, but only with respect to such property;
(ii) “Participation Facility” means any property in which Warrantor (or a Warrantor Subsidiary) participates in the management of such property and, where required by the context, includes the owner or operator of such property, but
only with respect of such property; (iii) “Trust Property” means any property with respect to which Warrantor (or a Warrantor Subsidiary) acts or has acted as a trustee or other fiduciary, directly or indirectly, and includes any
trust or similar legal vehicle that owns or controls (or that owned or controlled) such property and, where required by the context, includes the trustee or other fiduciary, but only with respect to such property; and (iv) “Hazardous
Material” means any pollutant, contaminant or hazardous substance within the meaning of the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. Section 9601 et seq., or any similar federal, state or local law.

 5.18 Knowledge as to Conditions. On the date of this Agreement, Warrantor knows of no reason why the regulatory approvals,
authorizations, filings, registrations and notices contemplated by Section 8.5 should not be obtained without the imposition of any material and adverse condition or restriction. 
 5.19 Labor Matters. Except as set forth on Schedule 5.19, neither Warrantor is a party to, or is bound by, any collective bargaining
agreement, contract or other agreement or understanding with a labor union or labor organization, nor is Warrantor the subject of any proceeding asserting that Warrantor has committed an unfair labor practice or seeking to compel Warrantor to
bargain with any labor union or labor organization as to wages and conditions of employment; nor is there any strike or other labor dispute involving Warrantor pending or threatened. 
 5.20 Fairness Opinion. PIC shall have received a written opinion from Stifel, Nicolaus & Company, Incorporated, PIC’s
financial advisor, dated the date of this Agreement, to the effect that, as of such date, the Per Share Merger Consideration to be received by the holders of PIC Common Stock is fair to PIC’s stockholders from a financial point of view.

 5.21 Materiality. No representation or warranty by a Warrantor contained in this Section V shall be deemed untrue or incorrect, and
no party hereto shall be deemed to have breached a representation or warranty, on account of the existence of any fact, circumstance or event unless, as a direct or indirect consequence of such fact, circumstance or event, individually or taken
together with all other facts, circumstances or events inconsistent with any paragraph of Section V, as applicable, there is or is reasonably likely to be a Material Adverse Effect, except that the representations and warranties in Sections 5.1,
5.2, 5.3 and 5.4 shall be true and correct in all respects. PIC’s representations, warranties and covenants contained in this Agreement shall not be deemed to be untrue or breached as a result of effects arising solely from actions taken in
compliance with this Agreement or a written request of IBKC. 
  

 - 14 - 

 SECTION VI. 
 COVENANTS AND AGREEMENTS 
 Each of the parties to this Agreement hereby covenants and agrees with the
other parties as follows: 
 6.1 Conduct of Business — Negative Covenants. From the date of this Agreement until the earlier of
the Effective Date or until the termination of this Agreement, except as otherwise permitted by this Agreement or as set forth on Schedule 6.1, PIC will not do, or agree or commit to do, and will cause each of its Subsidiaries not to do or
agree to commit to do, any of the following without the prior written consent of a duly authorized officer of IBKC, which consent will not be unreasonably withheld: 
 (a) Amend its charter, by-laws, or other governing instruments, or 
 (b) Impose, or suffer the imposition,
on any share of capital stock held by it or by one of its Subsidiaries, of any material lien, charge or encumbrance, or permit any such lien, charge or encumbrance to exist, or 
 (c) Repurchase, redeem, or otherwise acquire or exchange, directly or indirectly, any shares of its capital stock or any securities convertible into any
shares of its capital stock, or 
 (d) Except as expressly contemplated by this Agreement, acquire direct or indirect control over any
corporation, association, firm or organization, other than in connection with (i) internal reorganizations or consolidations involving existing Subsidiaries, (ii) good faith foreclosures in the ordinary course of business,
(iii) acquisitions of control by a banking Subsidiary in a bona fide fiduciary capacity, (iv) investments made by small business investment corporations or by Subsidiaries that invest in unaffiliated companies in the ordinary
course of business, or (v) the creation of new Subsidiaries organized to conduct or continue activities otherwise permitted by this Agreement, or 
 (e) Except as set forth on Schedule 6.1(e), issue, sell, pledge, encumber, authorize the issuance of, or otherwise dispose of: (i) any shares of its capital stock, including any agreement to issue, sell,
pledge, encumber, or authorize the issuance of its capital stock; (ii) any substantial part of its assets or earning power; or (iii) any asset other than in the ordinary course of business for reasonable and adequate consideration, or

 (f) Adjust, split, combine, or reclassify any capital stock of PIC or issue or authorize the issuance of any other securities in respect
of or in substitution for PIC Common Stock, or 
 (g) Except as set forth on Schedule 6.1(g), incur any additional material debt
obligation or other material obligation for borrowed money, except in the ordinary course of its business consistent with past practices (and such ordinary course of business shall include, but shall not be limited to, Federal Home Loan Bank
advances, the creation of deposit liabilities, purchases of federal funds, sales of certificates of deposit and entry into repurchase agreements), or 
 (h) Except as set forth on Schedule 6.1(h), grant any increase in compensation or benefits to its officers or other employees; pay any bonus not in accordance with Schedule 6.1(h) or as set forth below,
enter into any severance agreements with any of its directors or officers; grant any increase in fees or other increases in compensation or other benefits to any of its present or former directors; or effect any change in retirement benefits for any
class of its employees or officers (unless such change is required by applicable law or, in the opinion of counsel, is necessary or advisable to maintain the tax qualification of any plan under which the retirement benefits are provided) that would
increase the retirement benefit liabilities of PIC and its Subsidiaries. 
  

 - 15 - 

 (i) Except as contemplated by this Agreement, or any of the agreements, documents or instruments
contemplated hereby, or as set forth on Schedule 6.1(i), amend any existing employment, severance or similar contract between it or any of its Subsidiaries (unless such amendment is required by law), or enter into any new such contract with,
any person, or 
 (j) Except as contemplated by this Agreement or any of the agreements, documents or instruments contemplated hereby, or set
forth in Schedule 6.1(j), adopt any new employee benefit plan or make any material change in or to any existing employee benefit plan, other than any such change that is required by law or that, in the opinion of counsel, is necessary or
advisable to maintain the tax qualified status of any such plan, or 
 (k) Place or suffer to exist on any of it assets or properties any
mortgage, pledge, lien, charge or other encumbrance, other than in the ordinary course of business consistent with past practices, or as disclosed in Schedule 6.1(k), cancel any material indebtedness to it or any material claims which it may
have had, or waive any right of substantial value or discharge or satisfy any material noncurrent liability, or 
 (l) Charge off (except as
may otherwise be required by law or by regulatory authorities or by GAAP consistently applied) any material Credit, or make or enter into any commitments to make any Credit which varies materially from its written credit policies, copies of which
have been made available to IBKC, or 
 (m) Reduce its reserve for loan losses below $4.0 million, except as may be required by law,
regulatory authority or GAAP, or 
 (n) Other than in the normal course of providing credit to customers as part of its banking business,
accepting deposits and making investments, enter into any contract or series of related contracts involving a payment of more than $50,000. 
 (o) Commit to do any of the foregoing. 
 6.2 Conduct of Business — Affirmative Covenants. Unless the prior
written consent of the other Warrantor shall have been obtained, except as otherwise contemplated or permitted hereby or as set forth on Schedule 6.2, each Warrantor shall operate its business only in the ordinary course of business of such
Warrantor consistent with past practices, shall preserve intact its business organizations and assets and maintain its rights and franchises, and shall voluntarily take no action which would (i) adversely affect the ability of any of them to
obtain any necessary approvals of Regulatory Authorities required for the transactions contemplated hereby without imposition of a condition or restriction of the type referred to in the second sentence of Section 8.5 of this Agreement,
(ii) adversely affect the ability of such Warrantor to perform its obligations under this Agreement, or (iii) cause or permit a breach of any of its covenants or cause or permit any representation or warranty of it to become untrue in any
material respect, as if each such representation and warranty were continuously made from the date hereof. 
 6.3 Adverse Changes
in Condition. Each Warrantor shall give written notice promptly to the other Warrantor concerning (i) any event which has had, or is reasonably likely to have, a Material Adverse Effect on such Warrantor, or (ii) the occurrence or
impending occurrence of any event or circumstance known to such Warrantor which would have needed to be reported in a Disclosure Schedule hereunder if it had occurred or been pending on or prior to the date of this Agreement, or which would cause or
constitute a material breach of any of the representations, warranties or covenants of such Warrantor contained herein or that would reasonably be expected to materially and adversely affect the timely consummation of the transactions contemplated
hereby. Each Warrantor shall use its reasonable best efforts to prevent or to promptly remedy the same. 
  

 - 16 - 

 6.4 Investigation and Confidentiality. 
 Prior to the Effective Date, each Warrantor will keep the other Warrantor promptly advised of all material developments relevant to its business and to
the consummation of the Merger and may make or cause to be made such investigation, if any, of the business, properties, operations and financial and legal condition of the other Warrantor and its Subsidiaries as such Warrantor reasonably deems
necessary or advisable to familiarize itself and its advisors with such business, properties, operations and condition; provided, however, that such investigation shall be reasonably related to the transactions contemplated hereby and shall not
interfere unnecessarily with normal operations. Each Warrantor agrees to furnish the other Warrantor and the other Warrantor’s respective advisors with such financial and operating data and other information with respect to its business,
properties and employees as the other Warrantor shall from time to time reasonably request. No investigation by one Warrantor shall affect the representations and warranties of the other Warrantor and, subject to Section 9.3 of this Agreement,
each such representation and warranty shall survive any such investigation. Each Warrantor agrees to furnish the other Warrantor with all information necessary to expedite pre-conversion planning and implementation, including, but not limited to,
all things necessary, proper or advisable under applicable laws and regulations to plan, make effective and consummate systems and branch conversions. Notwithstanding the foregoing, neither party hereto shall be required to provide access to or to
disclose information where such access or disclosure would violate its attorney-client privilege or violate or prejudice the rights of any customer or contravene any law, rule, regulation, order or judgment, nor to disclose board minutes of any
confidential discussion of this Agreement and the transactions contemplated hereby. Each Warrantor shall maintain the confidentiality of all confidential information furnished to it by the other Warrantor in accordance with the terms of the
confidentiality agreement dated June 12, 2006 between the Warrantors (the “Confidentiality Agreement”). 
 6.5
Reports. From the date of this Agreement to the earlier of the Effective Date or the termination of this Agreement, each Warrantor shall, IBKC shall cause IBERIABANK to, and PIC shall cause PBT to, file all reports required to be filed by
such Warrantor, PBT and IBERIABANK with any Regulatory Authority, and shall deliver to the other Warrantor copies of all such reports promptly after the same are filed. 
 6.6 Dividends. From the date of this Agreement to the earlier of the Effective Date or the termination of this Agreement, PIC shall not declare or pay any dividend or other distribution to its
stockholders; provided, however, that PIC may (to the extent legally able to do so), but shall not be obligated to, declare and pay consistent with past practices and prior to the Effective Date, a quarterly cash dividend (in an amount per share not
to exceed the amount disclosed in Schedule 6.6), which with respect to the fiscal quarter of the Effective Date shall be prorated based on the number of elapsed full weeks prior to thereto and paid prior to the Closing. 
 6.7 Capital Stock. Except as otherwise contemplated by this Agreement (including Section 6.1(e) hereof), or as set forth on
Schedule 6.7, without the prior written consent of IBKC, from the date of this Agreement to the earlier of the Effective Date or the termination of this Agreement, PIC shall not, and shall not enter into any agreement to, issue, sell, or
otherwise permit to become outstanding any additional shares of PIC Common Stock or any other capital stock of PIC and any Subsidiary of PIC, or any stock appreciation rights, or any option, warrant, conversion or other right to acquire any such
stock, or any security convertible into any such stock. 
 6.8 Agreement of Affiliates. PIC shall deliver to IBKC, no later
than thirty (30) days after the date of this Agreement, a letter identifying each person whom it reasonably believes is an “affiliate” of PIC for purposes of Rule 145 under the 1933 Act. Thereafter and until the Effective Date, PIC
shall identify to IBKC each additional person whom PIC reasonably believes to have thereafter become an “affiliate”. PIC shall use its best efforts to cause each person who is identified as an “affiliate” of PIC pursuant to the
two (2) immediately preceding sentences who receives IBKC Common Stock in the Merger to deliver to IBKC, prior to the Effective Date, a written agreement, substantially in the form of Exhibit II. 
  

 - 17 - 

 6.9 Certain Actions. 
 (a) Subject to Section 6.9(d) of this Agreement, PIC agrees that, from the date of this Agreement until the earlier of the Effective Date or the termination of this Agreement, neither it nor any of its
affiliates, nor any of the officers and directors of it or its affiliates shall, and that it shall cause its and its affiliates’ employees, agents and representatives (including any investment banker, attorney or accountant retained by it or
any of its affiliates) not to, directly or indirectly, (i) initiate, solicit, encourage or knowingly facilitate any inquiries or the making of any Acquisition Proposal, (ii) have any discussion with or provide any confidential information
or data to any Person relating to an Acquisition Proposal, or engage in any negotiations concerning an Acquisition Proposal, or knowingly facilitate any effort or attempt to make or implement an Acquisition Proposal, (iii) approve or recommend,
or propose publicly to approve or recommend, any Acquisition Proposal or (iv) approve or recommend, or propose to approve or recommend, or execute or enter into any letter of intent, agreement in principle, merger agreement, acquisition
agreement, option agreement or other similar agreement or propose publicly or agree to do any of the foregoing related to any Acquisition Proposal. 
 (b) PIC agrees that it will, and will cause its officers, directors and representatives to, immediately cease and cause to be terminated any activities, discussions or negotiations existing as of the date of this Agreement with any parties
conducted heretofore with respect to any Acquisition Proposal informing them that the Board of Directors no longer seeks the making of any Acquisition Proposals. 
 (c) PIC agrees that it will use reasonable best efforts to promptly inform its directors, officers, key employees, agents and representatives of the obligations undertaken in this Section 6.9. 
 (d) Notwithstanding the provisions of Section 6.9(a) of this Agreement, if any Person after the date of this Agreement submits to PIC’s board
of directors an unsolicited, bona fide, written Acquisition Proposal, and PIC’s board of directors reasonably determines in good faith, after receipt of advice from outside legal counsel, that the failure to engage in discussions
with such Person concerning such Acquisition Proposal may cause PIC’s board of directors to breach its fiduciary duties to PIC and its stockholders, and after consultation with its financial advisor, then, in such case, (i) PIC may
(A) furnish information about its business to such Person under protection of an appropriate confidentiality agreement containing customary limitations on the use and disclosure of all non-public written or oral information furnished to such
Person, provided that PIC must contemporaneously furnish to IBKC all such non-public information furnished to such Person, and (B) negotiate and participate in discussions and negotiations with such Person; and (ii) if PIC’s board of
directors determines that such an Acquisition Proposal is a Superior Proposal (defined below), PIC’s board of directors may (subject to the provisions of this Section 6.9) (A) withdraw or adversely modify its approval or
recommendation of the Merger and recommend such Superior Proposal or (B) terminate this Agreement, in each case, (i) at any time after five (5) Business Days following IBKC’c receipt of written notice (a “Notice of Superior
Proposal”) advising IBKC that PIC’s board of directors has received a Superior Proposal and enclosing a copy of the Acquisition Proposal, identifying the Person submitting the Superior Proposal, specifying the material terms and conditions
of such Superior Proposal, and (ii) subject to IBKC’s Right of First Refusal (defined below). In the event IBKC elects not to exercise the Right of First Refusal, PIC shall provide IBKC with a final written notice of acceptance before or
simultaneous with accepting any Superior Proposal. For purposes of this Agreement, “Superior Proposal” means any unsolicited, bona fide, written Acquisition Proposal for consideration consisting of cash and/or securities, and
otherwise on terms which PIC’s board of directors determines, after consultation with its financial advisor, are more favorable to PIC’s stockholders (in their capacities as stockholders) from a financial point of view than the Merger
after giving effect to the provisions of Section 9.2 (or other revised proposal submitted by IBKC). For the purposes of this Section 6.9(d), an Acquisition Proposal shall be “bona fide” if the board of directors of
PIC reasonably determines that the Person submitting such Acquisition Proposal is capable, from a financial, regulatory and other appropriate perspectives, of consummating such Acquisition Proposal on the terms proposed. 
 (e) IBKC shall have the right (“Right of First Refusal”) for five (5) Business Days after receipt of Notice of Superior Proposal to make
such adjustments in the terms and conditions of this Agreement as would enable PIC to proceed with the Merger on the basis of such adjusted terms. If IBKC fails to exercise such Right of First Refusal within the time herein specified, PIC shall be
at liberty to accept the Superior Proposal, subject to the obligations of PIC pursuant to Section 9.2 hereof. 
  

 - 18 - 

 6.10 Agreement as to Efforts to Consummate. Subject to the terms and conditions of this
Agreement and its fiduciary duties under applicable law, each Warrantor agrees to use, and to cause its Subsidiaries to use, its reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things,
necessary, proper or advisable under applicable laws and regulations to consummate and make effective, as soon as practicable after the date of this Agreement, the transactions contemplated by this Agreement, including, without limitation, using its
best efforts to lift or rescind any injunction or restraining order or other order adversely affecting the ability of any party hereto to consummate the transactions contemplated hereby. Each Warrantor shall use, and shall cause each of its
Subsidiaries to use, its reasonable best efforts to obtain consents of all third parties and governmental bodies necessary or desirable for the consummation of the transactions contemplated by this Agreement. This Section 6.10 shall not require
either Warrantor to waive any condition to such Warrantor’s obligation to consummate the Merger. 
 6.11 Operating
Functions. PIC and PBT shall cooperate with IBKC and IBERIABANK in connection with planning for the efficient and orderly combination of the parties and the operation of PBT after the Merger, and in preparing for the consolidation of appropriate
operating functions to be effective on the Effective Date. 
 6.12 Preservation of Business. PIC shall use its reasonable best efforts
to preserve the possession and control of all of PIC’s and PBT’s assets (other than those consumed or disposed of for value in the ordinary course), and the goodwill of customers and others having business relations with them, and will do
nothing knowingly to impair their ability keep and preserve their businesses as they exist on the date hereof. From the date hereof until the Effective Date, PBT (i) shall notify IBERIABANK prior to establishing the rates to be paid by PBT on
its deposit accounts, (ii) shall meet with IBERIABANK biweekly at PIC’s offices to review conduct of PIC’s loan approval process, and (iii) shall notify IBERIABANK promptly of any change that is material to the Credits identified
in Section 5.8(a).  
 6.13 Issuance of IBKC Common Stock. IBKC shall, prior to the Closing, take such action as is
required to authorize and reserve for issuance the IBKC Common Stock to the stockholders of PIC pursuant to the Merger, and to permit such IBKC Common Stock to be approved for listing and quotation on the NASDAQ Global Market. 
 6.14 Support and Non-Compete Agreements. PIC has delivered, or will deliver, to IBKC Support Agreements executed by James C. East and James
Hunter East, substantially in the form of Exhibit III. PIC shall use its reasonable best efforts to deliver to IBKC a Support Agreement executed by Mark Williamson. PIC has also delivered to IBKC Non-Compete Agreements substantially in the
form of Exhibit IV. 
 6.15 IBKC Capital and Financing. To the extent necessary to obtain regulatory approvals required to
consummate the Merger, IBKC shall use its best efforts to secure adequate capital financing, through a private placement, underwritten public offering or otherwise, in order to satisfy such regulatory requirements. 
 6.16 Election of IBKC Director. As of the Effective Date, IBKC shall elect James C. East to IBKC’s Board of Directors (subject to the right
of removal for cause), to serve until its 2008 Annual Meeting of Shareholders. At that time, the IBKC Board shall nominate Mr. East for an additional three-year term as an IBKC director. 
 SECTION VII. 
 ADDITIONAL AGREEMENTS 
 7.1 Registration Statement; Stockholder Approval. 
 (a) The Warrantors shall cooperate in the preparation of the Registration Statement. IBKC shall, as soon as practicable, file the Registration Statement with the SEC, and the Warrantors shall use their best efforts to
cause the Registration Statement to become effective under the 1933 Act. IBKC shall provide PIC and its counsel with a reasonable opportunity to review and comment on the Registration Statement, and shall incorporate all appropriate comments
thereto, prior to the time it is initially filed with the SEC or any amendments are filed with the SEC. IBKC shall take, and PIC shall cooperate with IBKC in connection with, any action required to be taken under the applicable state Blue Sky or
securities laws in connection with the issuance of shares of IBKC Common Stock 
  

 - 19 - 

 upon consummation of the Merger. Each Warrantor shall furnish all information concerning it and the holders of its
capital stock as the other Warrantor may reasonably request in connection with such action. PIC and IBKC shall promptly notify the other party if at any time it becomes aware that the Registration Statement contains any untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary to make the statements contained therein, in light of the circumstances under which they were made, not misleading. In such event, PIC shall cooperate with
IBKC in the preparation of a supplement or amendment to such Registration Statement that corrects such misstatement or omission, and IBKC shall file an amended Registration Statement with the SEC, and each of PIC and IBKC shall mail an amended Proxy
Statement to PIC’s stockholders. 
 (b) PIC and, if necessary, IBKC shall call a Stockholders Meeting to be held, if practicable, within
five (5) Business Days prior to the Effective Date for the purpose of considering and voting upon the Merger. In connection with the Stockholders Meeting, (i) PIC and, if necessary, IBKC shall mail the Proxy Statement to their respective
stockholders, (ii) each Warrantor shall furnish to the other Warrantor all information concerning it and its Subsidiaries that the other Warrantor may reasonably request in connection with the Proxy Statement, (iii) the Board of Directors
of PIC and, if necessary, IBKC shall, subject to its fiduciary duties under applicable law, recommend to its stockholders the approval of this Agreement and cause PIC and, if necessary, IBKC to use its best efforts to obtain such stockholder
approval. 
 7.2 Filings. Promptly following, or contemporaneous with, the Closing, the parties to this Agreement shall cause
to be made all filings as are required by applicable federal and state law, including filings required by the ABCA and BCL. 
 7.3
Tax Opinion. PIC agrees to use its best efforts to obtain a written opinion of Friday, Eldredge & Clark LLP, addressed to the Warrantors and reasonably satisfactory to IBKC’s counsel, dated the date of the Closing, subject to
customary representations and assumptions, and substantially to the effect that: 
 (i) the Merger will be treated for Federal income tax
purposes as a reorganization within the meaning of Section 368(a)(1)(A) of the Code, and IBKC and PIC will each be a party to the reorganization within the meaning of Section 368(b) of the Code, 
 (ii) no gain or loss will be recognized by IBKC or PIC as a result of the Merger, 
 (iii) a stockholder of PIC who receives IBKC Common Stock and cash in exchange for such stockholder’s shares of PIC Common Stock generally will
recognize gain, but not loss, to the extent of the lesser of: (1) the excess, if any, of (a) the sum of the aggregate fair market value of the IBKC Common Stock received (including any fractional share of IBKC Common Stock deemed to be
received and exchanged for cash) and the amount of cash received (including any cash received in lieu of a fractional share of IBKC Common Stock) over (b) the stockholder’s aggregate tax basis in the shares of PIC Common Stock exchanged in
the Merger; and (2) the amount of cash received, 
 (iv) the aggregate tax basis of the IBKC Common Stock received by a stockholder
of PIC who exchanges such stockholder’s PIC Common Stock in the Merger will equal such stockholder’s aggregate tax basis in the shares of PIC Common Stock being exchanged, reduced by any amount allocable to a fractioned share interest of
IBKC Common Stock for which cash is received and by the amount of any cash consideration received, and increased by the amount of taxable gain, if any recognized by such stockholder in the Merger, and 
 (v) the holding period of the shares of IBKC Common Stock received in the Merger will include the period during which the shares of PIC Common Stock
surrendered in exchange therefore were held, provided such shares of PIC Common Stock were held as capital assets at the Effective Date. 
 7.4 Press Releases. IBKC and PIC shall cooperate with each other in the development and distribution of all news releases and other public disclosures with respect to this Agreement or any of the transactions contemplated hereby, and
except as may be otherwise required by law, neither IBKC nor PIC shall issue any news release, or other public announcement or communication with respect to this Agreement without first consulting with the other party and using its best efforts to
provide the other party with the proposed news release, public announcement or communication prior to its distribution. It is understood that IBKC shall assume primary responsibility for the preparation of joint press releases relating to this
Agreement. 
  

 - 20 - 

 7.5 Applications. The Warrantors shall, and shall cause their Subsidiaries to, as soon as
practicable, prepare and file applications with the appropriate Regulatory Authorities seeking the approvals necessary to consummate the transactions contemplated by this Agreement. Each Warrantor shall have the right to review and approve in
advance all characterizations of the information relating to that party and any of its Subsidiaries that appear in any filing made in connection with the transactions contemplated by this Agreement with any Regulatory Authority. In addition, each
Warrantor shall furnish to the other party for review a copy of each such filing made in connection with the transactions contemplated by this Agreement with any Regulatory Authority prior to its filing. The Warrantors shall provide copies of all
such filings to each other within two (2) business days after such filings are made and shall promptly inform each other of all substantive regulatory contacts concerning the transactions contemplated by this Agreement. 
 7.6 Medical Claims. In the event of any termination or consolidation of any PIC or PIC Subsidiary health plan prior or subsequent to Closing, PIC
and its Subsidiaries will use their reasonable best efforts to cause their employees to submit all bills and receipts representing claims for reimbursement of medical expenses incurred prior to the effective date of such termination or
consolidation. 
 7.7 PBT Profit Sharing and 401(k) Plan. The PBT Profit Sharing and 401(k) Plan (the “Plan”) shall be
terminated as of, or immediately prior to, the Effective Date. All outstanding Plan indebtedness shall be repaid as soon as practicable following the Effective Date, and the balance of the shares and any other assets remaining in the loan suspense
account shall be allocated and distributed to Plan participants (subject to the receipt of a favorable determination letter from the Internal Revenue Service), as provided for in the Plan and unless otherwise required by applicable law. Prior to the
Effective Date, PBT, and following the Effective Date, IBERIABANK, shall use their respective best efforts in good faith to obtain such favorable determination letter (including, but not limited to, making such changes to the Plan and the proposed
allocations as may be requested by the Internal Revenue Service as a condition to its issuance of a favorable determination letter). Prior to the Effective Date, PBT, and following the Effective Date, IBERIABANK, will adopt such amendments to the
Plan as may be reasonably required by the Internal Revenue Service as a condition to granting such favorable determination letter on termination. Following the effective date of the Plan’s termination, neither PBT, prior to the Effective Date,
nor IBERIABANK, following the Effective Date, shall make any distribution from the Plan except as may be required by applicable law until receipt of such favorable determination letter. In the case of a conflict between the terms of this
Section 7.7 and the terms of the Plan, the terms of the Plan shall control; provided, however, in the event of any such conflict, PBT, before the Effective Date, and IBERIABANK, after the Effective Date, shall use their best efforts to cause
the Plan to be amended to conform to the requirements of this Section 7.7. 
 7.8 Employment Agreements. Prior to the date hereof
and effective as of the Effective Date, IBKC agrees that: (i) James Hunter East will enter into an Employment Agreement with PBT substantially in the form of Exhibit V, (ii) Robert C. Magee will enter into an Employment Agreement
with PBT substantially in the form of Exhibit VI, (iii) Michael B. Pryor will enter into an Employment Agreement with Lenders Title Company substantially is the form of Exhibit VII, and (iv) Charles Quick will enter into an
Employment Agreement with Pulaski Mortgage Company substantially in the form of Exhibit VIII (collectively, the “Post-Merger Employment Agreements”). Each of the existing employment agreements, if any, of such individuals with PIC
and the PIC Subsidiaries listed on Schedule 7.8 (collectively, the “Pre-Merger Employment Agreements”) shall be terminated as of or immediately prior to the Effective Date and superseded by the respective Post-Merger Employment
Agreement, each employee shall receive any payments that such employee is entitled to receive under his existing Pre-Employment Agreement on the Effective Date (and, as applicable, Schedule 2.3(a)); provided, however, that no payments or
benefits to officers of PIC or its Subsidiaries in connection with the Merger shall constitute an excess parachute payment under Section 280G of the Code (or, if so, the Total Merger Consideration shall be reduced by an amount equal to the
additional income tax incurred by PIC and its Subsidiaries as a result of the disallowance of the deduction applicable thereto). 
 7.9
Organization of IBAC. IBKC shall cause IBAC to be organized under the laws of Louisiana. The Board of IBAC shall approve this Agreement and the Merger, whereupon IBAC shall become a party to, and be bound by, this Agreement, and IBKC shall adopt
and ratify this Agreement in its capacity as the sole stockholder of IBAC. 
  

 - 21 - 

 SECTION VIII. 
 CONDITIONS PRECEDENT TO OBLIGATIONS TO CONSUMMATE 
 The obligation of each Warrantor to consummate
the Merger is subject to the satisfaction of each of the following conditions, unless waived by such party pursuant to Section 10.5 of this Agreement: 
 8.1 Representations and Warranties. The representations and warranties of the other Warrantor set forth or referred to in this Agreement shall be true and correct as of the date of this Agreement and as of the
time of the Closing with the same effect as though all such representations and warranties had been made on and as of the time of the Closing, in each case subject to the standard set forth in Section 5.21 hereof, except (i) for any such
representations and warranties made as of a specified date, which shall be true and correct as of such date or (ii) as expressly contemplated or permitted by this Agreement. 
 8.2 Performance of Agreements and Covenants. Each and all of the agreements and covenants of the other Warrantor to be performed and
complied with pursuant to this Agreement and the other agreements contemplated hereby prior to the time of the Closing shall have been duly performed and complied with by it in all material respects. 
 8.3 Certificates. Each Warrantor shall have delivered to the other Warrantor a certificate, dated as of the time of the Closing and signed
on its behalf by its chief executive officer and its chief financial officer, to the effect that the conditions of its obligations set forth in Section 8.1 and Section 8.2 of this Agreement with respect to it have been satisfied, all in
such reasonable detail as the other Warrantor shall request. 
 8.4 Stockholder Approval. The stockholders of PIC and, if
necessary, IBKC shall have approved this Agreement, the Merger and the consummation of the transactions contemplated hereby, as and to the extent required by law and by the provisions of the governing instruments of PIC, and if necessary under
applicable law or NASDAQ listing standards, IBKC, and PIC shall have furnished to IBKC certified copies of resolutions duly adopted by its stockholders evidencing the same. Holders of not more than 10% of the PIC Common Stock shall have exercised
statutory rights of dissent and appraisal pursuant to the ABCA. 
 8.5 Consents and Approvals. All material approvals and
authorizations of, filings and registrations with, and notifications to, all Regulatory Authorities required for consummation of the Merger shall have been obtained or made and shall be in full force and effect and all waiting periods required by
law shall have expired. Any approval obtained from any Regulatory Authority which is necessary to consummate the transactions contemplated hereby shall not contain any material adverse non-standard term or condition which in the reasonable judgment
of the Board of Directors of IBKC so materially and adversely affects the economic or business assumptions of the transactions contemplated by this Agreement so as to render inadvisable the consummation of the Merger; provided, however, to the
extent the regulatory condition relates to additional capital, IBKC shall comply with its covenant set forth in Section 6.15 of this Agreement. To the extent that any lease, license, loan or financing agreement or other contract or agreement to
which Warrantor is a party requires the consent of or waiver from the other party thereto as a result of the transactions contemplated by this Agreement, such consent or waiver shall have been obtained, unless the failure to obtain such consent or
waiver would not, following the Merger, have a Material Adverse Effect on such Warrantor. 
 8.6 Legal Proceedings. No
Warrantor shall be subject to any order, decree or injunction of a court or agency of competent jurisdiction which enjoins or prohibits consummation of any of the transactions contemplated by this Agreement. 
 8.7 Tax Matters. Each Warrantor shall have received the tax opinion addressed to it referred to in Section 7.3 of this Agreement. No
payments or benefits to officers of PIC or its Subsidiaries in connection with the Merger shall constitute an excess parachute payment under Section 280G of the Code (or, if so, PIC may satisfy this condition by reducing the Total Merger
Consideration by an amount equal to the additional income tax incurred by PIC and its Subsidiaries as a result of the disallowance of the deduction applicable thereto). 
  

 - 22 - 

 8.8 Registration Statement. The Registration Statement shall be effective under the 1933
Act, no stop order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose shall be pending before or threatened by the SEC. 
 8.9 Simultaneous Transactions. The Warrantors shall have executed all documents and taken all such other action as are necessary to
effectuate the Merger other than filings referred to in Section 7.2, and the Warrantors shall have irrevocably authorized their agents to make such filing in its behalf. 
 8.10 Legal Opinions. Each Warrantor shall have received an opinion from counsel for the other Warrantor, dated as of the Effective Date,
with respect to such matters and in such form as shall be agreed upon between counsel for each Warrantor. As to matters involving the application of Arkansas law, and to the extent reasonably satisfactory in form and scope to counsel for IBKC,
counsel for PIC may rely on the opinion of other counsel, provided that a copy of such opinion is delivered to IBKC and its counsel. 
 8.11 NASDAQ Listing. The shares of IBKC common stock to be issued in the Merger shall have been authorized for listing on the NASDAQ Global Market. 
 8.12 Payment of Merger Consideration. As a condition to PIC’s obligation to consummate the Merger, IBKC shall have delivered the Exchange Fund to the Exchange Agent on or before the Closing Date and the
Exchange Agent shall provide PIC with a certificate evidencing such delivery. 
 8.13 No Material Adverse Effect. Since
December 31, 2005, no event has occurred or circumstance arisen that, individually or in the aggregate, has had a Material Adverse Effect on the other Warrantor. 
 SECTION IX. 
 TERMINATION 
 9.1 Termination. Notwithstanding any other provision of this Agreement and notwithstanding the approval of this Agreement by the
stockholders of PIC, this Agreement may be terminated and the Merger abandoned at any time prior to the Closing: 
 (a) By mutual consent of
the Boards of Directors of the Warrantors; or 
 (b) By the Board of Directors of either Warrantor (provided that the terminating party is
not then in material breach of any representation, warranty, covenant or other agreement contained in this Agreement) in the event of a material breach by the other Warrantor of any representation, warranty, covenant or agreement of such other
Warrantor contained herein which would result in the failure to satisfy the closing condition set forth in Section 8.1 or 8.2 of this Agreement, which breach cannot be or has not been cured within thirty (30) days after the giving of a
written notice to the breaching Warrantor of such material breach; or 
 (c) By the Board of Directors of either Warrantor in the event that
the Merger shall not have been consummated within twelve (12) months after the date of this Agreement; or 
 (d) By the Board of
Directors of either Warrantor in the event any approval of any Regulatory Authority required for consummation of the Merger and the other transactions contemplated hereby shall have been denied by final non-appealable action of such Regulatory
Authority or if any such action taken by such Regulatory Authority is not appealed within the time limit for appeal; or 
 (e) Subject to the
compliance with Section 6.15, by the Board of Directors of IBKC, in the event any such approval of any Regulatory Authority required for consummation of the Merger and the other transactions contemplated hereby is conditioned upon the
satisfaction of any material adverse condition or requirement that, in the reasonable opinion of IBKC, would so materially adversely affect its business or the economic benefits of the Merger as to render consummation of the Merger inadvisable or
unduly burdensome, and the time period for appeals and request for reconsideration has run; or 
  

 - 23 - 

 (f) By the Board of Directors of either Warrantor, if the stockholders of PIC or, if necessary under
applicable law or NASDAQ listing standards, IBKC fail to approve this Agreement and the consummation of the transactions contemplated hereby at the Stockholders Meeting; or 
 (g) By the Board of Directors of either Warrantor (provided that the terminating party is not then in material breach of any representation, warranty,
covenant or other agreement contained in this Agreement) in the event that any of the conditions precedent to the obligations of such Warrantor to consummate the Merger cannot be satisfied or fulfilled within twelve (12) months after the date
of this Agreement; or 
 (h) By the Board of Directors of IBKC if the Board of Directors of PIC shall, or shall have resolved to, withdraw,
modify or change its recommendation to PIC’s stockholders of this Agreement or the Merger, or recommend any Acquisition Transaction other than the Merger; or 
 (i) By the Board of Directors of either Warrantor if the other Warrantor has experienced, or is reasonably likely to experience, a Material Adverse Effect, which is not remedied or cured within thirty (30) days
after notice of intention to terminate is given by the Warrantor invoking this Section 9.1(i), which notice shall specify the nature of the matter or matters constituting such Material Adverse Effect and which are the basis of such intention;
provided, however, that the right to terminate that is specified in such notice of intention shall itself terminate unless notice of termination is given by such Warrantor within fifteen (15) days following the end of such remedial or curative
period; or 
 (k) By the Board of Directors of PIC, pursuant to Section 6.9(d). 
 9.2 Effect of Termination. 
 (a) In the event of the termination and abandonment of this Agreement pursuant to Section 9.1 of this Agreement, this Agreement shall become void and have no effect and the parties hereto will be relieved of all obligations and
liabilities under this Agreement, except that: (i) the provisions of Sections IX and X hereof shall survive any such termination and abandonment; (ii) a termination pursuant to Section 9.1(b) of this Agreement shall not relieve a
breaching Warrantor from liability for any breach giving rise to such termination and the provisions of Section 9.2(c) or (d), as applicable; (iii) each Warrantor shall remain obligated under, and liable for any breach of, any of the
provisions of this Agreement that survive its termination.; and (iv) in the event this Agreement is terminated because of a failure by IBKC to comply with Section 6.15, IBKC shall remain liable for any breach of Section 6.15.

 (b) In the event this Agreement is terminated by IBKC pursuant to Section 9.1(b) hereof because of a willful breach of a
representation, warranty, covenant or other agreement by PIC, or pursuant to Section 9.1(f) hereof if the failure of the stockholders of PIC to approve this Agreement and the Merger, occurs after the receipt by PIC of an Acquisition Proposal,
or pursuant to Section 9.1(h) hereof, or by PIC pursuant to Section 9.1(k) hereof, and within twelve (12) months after the date of any such termination PIC, without IBKC’s prior written consent, accepts in a written agreement an
Acquisition Proposal, then PIC shall pay IBKC $6.4 million (the “Termination Fee”) not later than the fifth Business Day following the date PIC accepts such Acquisition Proposal. Upon payment of the Termination Fee pursuant to this
Section 9.2(b), IBKC will not have any other rights or claims against PIC or its Subsidiaries, or their respective officers and directors, under this Agreement. 
 (c) In the event this Agreement is terminated as a result of IBKC’s failure to satisfy any of its representations, warranties or covenants set forth herein, IBKC shall reimburse PIC for its reasonable
out-of-pocket expenses relating to the Merger in an amount not to exceed $200,000, which amount shall not be deemed an exclusive remedy or liquidated damages. 
 (d) In the event this Agreement is terminated as a result of PIC’s failure to satisfy any of its representations, warranties or covenants set forth herein, PIC shall reimburse IBKC for its reasonable
out-of-pocket expenses relating to the Merger in an amount not to exceed $200,000, which amount shall not be deemed an exclusive remedy or liquidated damages. 
  

 - 24 - 

 9.3 Survival of Representations, Warranties and Covenants. The respective representations,
warranties, obligations, covenants and agreements of the Warrantors shall not survive the Effective Date, except for those covenants and agreements contained in this Agreement which by their terms apply in whole or in part after the Effective Date;
provided, however, that no such representations, warranties or covenants shall be deemed to be terminated or extinguished so as to deprive any Warrantor (or any director, officer or controlling Person thereof) of any defense in law or equity which
otherwise would be available against the claims of any Person, including, without limitation, any stockholder or former stockholder of any Warrantor, the aforesaid representations, warranties and covenants being material inducements to consummation
by the Warrantors of the transactions contemplated hereby. 
 SECTION X. 
 MISCELLANEOUS 
 10.1 Expenses. 
 (a) Except as otherwise provided in this Agreement, each of the parties hereto shall bear and pay all costs and expenses, incurred by it or on its behalf
in connection with the transactions contemplated hereunder, including fees and expenses of its own financial or other consultants, investment bankers, accountants and counsel. 
 (b) Final settlement with respect to payment of fees and expenses by the parties hereto shall be made within thirty (30) days of the termination of
this Agreement. 
 10.2 Brokers and Finders. Except as set forth on Schedule 10.2, PIC represents and warrants that
neither it nor any of its officers, directors, employees, affiliates or Subsidiaries has employed any broker or finder or incurred any liability for any financial advisory fees, investment bankers’ fees, brokerage fees, commissions or
finders’ fees in connection with this Agreement or the transactions contemplated hereby. 
 10.3 Entire Agreement. Except as
otherwise expressly provided herein, this Agreement, including the exhibits and schedules hereto, and the Confidentiality Agreement contain the entire agreement among the parties hereto with respect to the transactions contemplated hereunder and
thereunder, and such agreements supersede all prior arrangements or understanding with respect thereto, written or oral. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the parties hereto and their
respective successors. Nothing in this Agreement, expressed or implied, is intended to confer upon any party, other than the parties hereto or their respective successors, any rights, remedies, obligations or liabilities under or by reason of this
Agreement except for (i) the rights of stockholders of PIC to receive the Merger Consideration following the Effective Date and (ii) the provisions of Section 4.4, which shall inure to the benefit of and be enforceable by the Persons
referenced therein. 
 10.4 Amendments. To the extent permitted by law, this Agreement may be amended by a subsequent writing signed
by each of the parties hereto upon the approval of the boards of directors of such parties; provided, however, that the provisions of this Agreement relating to the manner or basis in which shares of PIC Common Stock will be exchanged for IBKC
Common Stock and cash shall not be amended after the PIC Stockholders Meeting without the requisite approval of the holders of the issued and outstanding shares of PIC Common Stock entitled to vote thereon. The parties hereto may, without approval
of their respective boards of directors, make such technical changes to this Agreement, not inconsistent with the purposes hereof and thereof, as may be required to effect or facilitate any governmental approval or acceptance of the Merger or of
this Agreement or to effect or facilitate any filing or recording required for the consummation of any of the transactions contemplated hereby or thereby. PIC agrees to take such reasonable actions requested by IBKC as may be reasonably necessary to
modify the structure of, or to substitute parties to (so long as such substitute is a Subsidiary of IBKC) the transactions contemplated hereby; provided, however, that such modification shall not change the amount, kind, manner or basis in which
shares of PIC Common Stock will be exchanged for IBKC Common Stock or abrogate the covenants and other agreements contained in this Agreement, result in adverse tax consequences to the stockholders of PIC, materially delay consummation of the Merger
or jeopardize the timely receipt of Regulatory Approvals. 
  

 - 25 - 

 10.5 Waivers. Prior to the Effective Date, each party hereto, acting through its Board of
Directors or chief executive officer or other authorized officer, shall, as to such party’s rights hereunder, have the right (i) to waive any default in the performance of any term of this Agreement by any other party, (ii) to waive
or extend the time for the compliance or fulfillment by any other party of any and all of the obligations under this Agreement, and (iii) to waive any or all of the conditions precedent to the obligations of such party under this Agreement. No
waiver or modification of this Agreement or of any covenant, condition, or limitation herein contained shall be valid unless in writing and duly executed by the party to be charged therewith. No evidence of any waiver or modification shall be
offered or received in evidence at any proceeding, arbitration, or litigation between the parties hereto arising out of or affecting this Agreement, or the rights or obligations of the parties hereunder, unless such waiver or modification is in
writing, duly executed as aforesaid. 
 10.6 No Assignment. No party hereto may assign any of its rights or obligations under this
Agreement to any other Persons, without the express written consent of the other parties and any such purported assignment without such requisite consent shall be null and void. 
 10.7 Notices. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if delivered by
hand, by facsimile transmission or by registered or certified mail, postage pre-paid, to the Persons at the addresses set forth below (or at such other address as may be provided hereunder), and shall be deemed to have been delivered as of the date
so delivered: 
 If to IBKC and/or IBERIABANK: 
 IBERIABANK Corporation 
 200 West Congress Street 
 Lafayette, LA 70501 
 Attention: Daryl G. Byrd 
                  President and Chief Executive Officer 
 With a copy to: 
 Jones, Walker, Waechter, Poitevent,
Carrère & Denègre, L.L.P. 
 2600 Virginia Avenue, N.W., Suite 1113 
 Washington, D.C. 20037 
 Attention: Edward B.
Crosland, Jr., Esq. 
 If to PIC: 
 Pulaski
Investment Corporation 
 5800 R Street 
 Little Rock, AR 72207 
 Attention: James C. East 
                  Chairman of the Board 
 With a copy to: 
 Friday, Eldredge & Clark LLP 
 Regions Center 
 400 West Capitol, Suite 2000

 Little Rock, AK 72201 
 Attention: Walter M. Ebel III, Esq. 
 10.8 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Louisiana without regard to the conflict of laws principles thereof. 
  

 - 26 - 

 10.9 Counterparts; Facsimile. This Agreement may be executed in one or more counterparts,
each of which shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile signature. 
 10.10 Captions. The captions contained in this Agreement are for reference purposes only and are not part of this Agreement. 
 In Witness Whereof, each of the parties to this Agreement has caused this Agreement to be executed on its behalf and attested by officers thereunto duly authorized all as of the day and year first above written. 
  

									
	IBERIABANK CORPORATION	 		 	PULASKI INVESTMENT CORPORATION
					
	By:	 	 /s/ Daryl G. Byrd
	 		 	By:	 	 /s/ James C. East

		 	Daryl G. Byrd	 		 		 	James C. East
		 	President and Chief Executive Officer	 		 		 	Chairman of the Board

 IBAC has joined as a party to this Agreement on this
     day of                     , 2006. 
  

			
	 IBERIABANK ACQUISITION
 CORPORATION

		
	By:	 	  

		 	Daryl G. Byrd
		 	President and Chief Executive Officer

  

 - 27 - 

 EXHIBIT I 
 AGREEMENT OF MERGER 
 THIS AGREEMENT OF MERGER (“Agreement”) is made as of
                    , 2006, between IBERIABANK Corporation (“IBKC”) and Pulaski Investment Corporation (“PIC”), in
connection with the Agreement and Plan of Merger, dated as of August     , 2006 (the “Plan”), between IBERIABANK Acquisition Corporation (“IBAC”) and IBERIABANK Corporation on the one hand and PIC on
the other. Capitalized terms not defined herein shall have their respective meanings set forth in the Plan. 
 ARTICLE 1: TERMS OF MERGER

 1.1 Merger. Subject to the terms and conditions hereof, at the Effective Date (defined herein), PIC shall be merged with and
into IBAC (the “Merger”), in accordance with, and with the effect provided in, the Louisiana Business Corporation Law (the “BCL”) and the Arkansas Business Corporation Act (the “ABCA”). 
 1.2 Assumption of Rights and Liabilities. At the Effective Date and thereafter, all the rights and property, real, personal, and mixed, of PIC,
shall be deemed to be transferred to and vested in IBAC without further act or deed; and the title to any real estate, or any interest therein, vested in IBAC shall not revert or be in any way impaired by reason of the Merger. All liabilities and
obligations of PIC of every kind and description shall be assumed by IBKC, and IBKC shall be bound thereby in the same manner and to the same extent that PIC was so bound at the Effective Date. 
 ARTICLE 2: MANNER OF CONVERTING SHARES 
 2.1 Conversion of PIC Common Stock. 
 (a) Except for shares of PIC Common Stock as to which dissenters’ shares have been
perfected and not withdrawn or otherwise forfeited (“Dissenters’ Shares”) under the ABCA, and as otherwise provided herein and in the Plan, at the Effective Date each outstanding share of PIC Common Stock will be converted into the
“Per Share Merger Consideration” which shall mean: 
 (i) .2274 shares of IBKC Common Stock (to the nearest
ten-thousandth of a share); plus 
 (ii) a number of shares of IBKC Common Stock equal to the quotient (rounded to the nearest
ten-thousandth of a share) obtained by dividing $13.323 by the average of the daily average trading prices of the IBKC Common Stock on the NASDAQ Global Market (or calculated by Bloomberg Screen AQR) on each of the fifteen (15) trading days ending
one (1) Business Day prior to the Effective Date; plus 
 (iii) an amount of cash (without interest) determined by dividing
$65.0 million by the number of shares of PIC Common Stock outstanding on the Effective Date (rounded to the nearest whole cent). No payments or benefits to officers of PIC or its Subsidiaries in connection with the Merger shall constitute an excess
parachute payment 

 under Section 280G of the Code (or, if so, PIC may satisfy this condition by reducing such total cash
payment by an amount equal to the additional income tax incurred by PIC and its Subsidiaries as a result of the disallowance of the deduction applicable thereto). 
 (b) Shares of PIC Common Stock that are held by PIC and any PIC subsidiary (other than shares held in a fiduciary capacity) shall not be considered to be outstanding and shall be cancelled (and not converted) by
virtue of the Merger at the Effective Time and without any further action by any party. 
 (c) If before the Effective Date, IBKC should
split or combine the IBKC Common Stock, or pay a stock dividend in IBKC Common Stock, or otherwise change the IBKC Common Stock into any other securities, or make any other dividend or distribution in respect of the IBKC Common Stock (other than
normal cash dividends as the same may be adjusted from time to time in accordance with or not in violation of this Agreement), then the Exchange Ratio will be appropriately adjusted to reflect such split, combination, dividend or other distribution
or change. 
 (d) In lieu of issuing any fractional share of IBKC Common Stock, each holder of PIC Common Stock who would otherwise be
entitled thereto, after aggregating into whole shares all fractional shares of IBKC Common Stock to which such holder is entitled by virtue of the Merger, upon surrender of the certificate(s) which represented PIC Common Stock, will receive cash
(without interest) equal to such fractional share multiplied by $58.60. 
 (e) No later than the Effective Date, IBKC shall deposit, or shall
cause to be deposited, with IBKC’s transfer agent, or such other third party experienced in the stock transfer business reasonably acceptable to PIC which shall act as an exchange agent, for the benefit of the holders of PIC Common Stock, for
exchange in accordance with this Section 2.1 and the Plan, certificates representing shares of IBKC Common Stock and the estimated amount of cash to be paid to the holders of PIC Common Stock. After the Effective Date, each holder of PIC Common
Stock (other than Dissenters’ Shares), upon surrender of such holder’s certificates in accordance herewith, will be entitled to receive the Per Share Merger Consolidation into which such holder’s shares have been converted, less any
applicable tax withholding. Until then, each certificate for PIC Common Stock will represent the Per Share Merger Consideration into which the shares of PIC Common Stock represented thereby were converted, except that IBKC may refuse to pay any
dividend or other distribution payable to holders of any unsurrendered certificate for PIC Common Stock (without any interest thereon) until surrender or if such dividend or distribution has reverted in full ownership to IBKC under its Articles of
Incorporation. Whether or not a certificate for PIC Common Stock is surrendered, after the Effective Date it will not represent any interest in any person other than IBKC. 
 ARTICLE 3: EFFECTIVENESS 
 3.1 Effectiveness. Consummation of the Merger is conditioned upon
the approval of this Agreement by the Board of Governors of the Federal Reserve System and necessary filings with the Louisiana Secretary of State and the Arkansas Secretary of State, and the other conditions set forth in the Plan. The Merger shall
become effective on the date and at the time this Agreement is filed with the Secretary of State of Louisiana and the Secretary of State of Arkansas (the “Effective Date”). 
  

 2 

 3.2 Additional Actions. If, after the Effective Date, IBAC shall believe any act to be necessary
or desirable to carry out the purposes of this Agreement, PIC and its proper officers and directors shall be deemed to have granted to IBKC an irrevocable power of attorney to do any such act, and the proper officers and directors of IBKC are fully
authorized in the name of PIC to take any and all such action. 
 ARTICLE 4: MISCELLANEOUS 
 4.1 Amendment. This Agreement or any exhibit or schedule may be amended or restated at any time by (i) the parties, by mutual agreement approved
by their Boards, except that the consideration to stockholders of PIC shall not be amended after approval of the Plan by PIC’s stockholders or (ii) by the parties’ chief executive officers or their designees to correct typographical errors
or to change erroneous references or cross references, or in any other manner not material to the substance of the Merger; provided, however, that no amendment shall be effective unless reduced to writing and executed by all parties to this
Agreement. The waiver by any party hereto of a breach of or noncompliance with any provision of this Agreement will not operate or be construed as a continuing waiver or a waiver or any other or subsequent breach or noncompliance hereunder.

 4.2 Termination. Prior to the Effective Date, this Agreement may be terminated, and the Merger abandoned, as set forth in the Plan,
and shall terminate on any termination of the Plan. 
 4.3 Counterparts. This Agreement may be executed in two or more counterparts,
each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. 
 4.4 Governing
Law. This Agreement shall be governed by, and interpreted in accordance with, the laws of the State of Louisiana applicable to contracts made and to be performed wholly within such State (except to the extent that mandatory provisions of Federal
law are applicable). 
 THE BOARD OF DIRECTORS OF PULASKI INVESTMENT CORPORATION 
  

					
	  
	 		  	  

			
	  
	 		  	  

			
	  
	 		  	  

			
	  
	 		  	  

			
	  
	 		  	  

  

 3 

 CERTIFICATE OF SECRETARY 
 OF IBERIABANK ACQUISITION CORPORATION 
 I hereby certify that the foregoing
Agreement was duly approved, without alteration or amendment, by the required vote of the Board of Directors of IBERIABANK Corporation. 
 Certificate dated
                    , 2006. 
  

	
	  

	 Secretary

 CERTIFICATE OF SECRETARY 
 OF PULASKI INVESTMENT CORPORATION 
 I hereby certify that the foregoing
Agreement was duly approved, without alteration or amendment, by the required vote of the Board of Directors and stockholders of Pulaski Investment Corporation. 
 Certificate dated                     , 2006. 
  

	
	  

	 Secretary

  

 4 

 EXECUTION BY CORPORATIONS 
 Considering the approval of this Agreement, as certified above, this Agreement is executed by such corporations, acting through their respective
Presidents, this          day of                     , 2006. 
  

									
	IBERIABANK CORPORATION	 		 	PULASKI INVESTMENT CORPORATION
					
	By:	 	  
	 		 	By:	 	  

	Its:	 	President	 		 	Its:	 	President

  

 5 

 ACKNOWLEDGMENT AS TO 
 IBERIABANK ACQUISITION CORPORATION 
 STATE OF LOUISIANA 
 PARISH OF LAFAYETTE 
 BEFORE ME, the undersigned authority,
personally came and appeared                     , who, being duly sworn, declared and acknowledged before me that he is the President of
IBERIABANK Acquisition Corporation and that in such capacity he was duly authorized to and did execute the foregoing Agreement on behalf of such corporation, for the purposes therein expressed and as his and such corporation’s free act and
deed. 
  

	
	  

	 Appearer

 Sworn to and subscribed before me 
 this          day of                     , 2006. 
  

	
	  

	 Notary Public

  

 6 

 ACKNOWLEDGMENT AS TO 
 PULASKI INVESTMENT CORPORATION 
 STATE OF ARKANSAS 
 COUNTY OF CRAIGHEAD 
 BEFORE ME, the undersigned authority, personally came and appeared
                    , who, being duly sworn, declared and acknowledged before me that he is the President of Pulaski Investment Corporation
and that in such capacity he was duly authorized to and did execute the foregoing Agreement on behalf of such corporation, for the purposes therein expressed and as his and such corporation’s free act and deed. 
  

	
	  

	 Appearer

 Sworn to and subscribed before me 
 this          day of                     , 2006. 
  

	
	  

	 Notary Public

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]